[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 62 of about 62
1. Saito SY, Maruyama Y, Kamiyama S, Nakahata N, Ohizumi Y: Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells. J Pharmacol Sci; 2004 May;95(1):41-6
Hazardous Substances Data Bank. (L)-EPHEDRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells.
  • Mao as well as MBS but not Saishin nor Bushi inhibited IgE-mediated histamine release from rat basophilic leukemia (RBL-2H3) cells.
  • Consistently, MBS and Mao but not Bushi nor Saishin increased cAMP levels in RBL-2H3 cells.
  • [MeSH-major] Cyclic AMP / biosynthesis. Drugs, Chinese Herbal / pharmacology. Ephedra. Ephedrine / analogs & derivatives. Histamine Release / drug effects. Immunoglobulin E / physiology. Immunosuppressive Agents / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / immunology. Male. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15153649.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Immunosuppressive Agents; 0 / mao-bushi-saishin-to; 37341-29-0 / Immunoglobulin E; 60VH42A1KJ / N-methylephedrine; E0399OZS9N / Cyclic AMP; GN83C131XS / Ephedrine
  •  go-up   go-down


2. Shinomiya F, Hamauzu Y, Kawahara T: Anti-allergic effect of a hot-water extract of quince (Cydonia oblonga). Biosci Biotechnol Biochem; 2009 Aug;73(8):1773-8
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the effect of a crude hot-water extract (HW) of quince (Cydonia oblonga Miller) fruit on type I allergy in vivo and in vitro.
  • Moreover, we found that quince HW inhibited the release of beta-hexosaminidase from rat basophilic leukemia cell line RBL-2H3 after a 24-h treatment.
  • These results suggest that quince HW had an inhibitory effect on type I allergy by suppressing IgE production and IgE-mediated degranulation.
  • [MeSH-minor] Administration, Oral. Animals. Cell Line, Tumor. Dermatitis, Atopic / blood. Dermatitis, Atopic / drug therapy. Humans. Immunoglobulin E / blood. Male. Mice. Phytotherapy. Rats. Receptors, IgE / metabolism. Skin / drug effects. Skin / pathology. beta-N-Acetylhexosaminidases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661701.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Plant Extracts; 0 / Receptors, IgE; 059QF0KO0R / Water; 37341-29-0 / Immunoglobulin E; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


3. Kaur S, Sur R, Liebel FT, Southall MD: Induction of prostaglandin D2 through the p38 MAPK pathway is responsible for the antipruritic activity of sertaconazole nitrate. J Invest Dermatol; 2010 Oct;130(10):2448-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STZ mitigated degranulation of RBL-2H3 (rat basophilic leukemia) mast cells induced by compound 48/80, a pruritogenic agent known to promote the release of histamine, and augmented PGD(2) production in mast cells and macrophages.
  • STZ induced p38 mitogen-activated protein kinase (MAPK) phosphorylation in mast cells and a pharmacological inhibitor of p38 MAPK, SB203580, resulted in the attenuation of PGD(2) levels.
  • [MeSH-major] Imidazoles / pharmacology. Macrophages / drug effects. Mast Cells / drug effects. Prostaglandin D2 / metabolism. Pruritus / drug therapy. Thiophenes / pharmacology. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Administration, Topical. Animals. Antifungal Agents / pharmacology. Cell Degranulation / drug effects. Cell Line. Drug Interactions. Histamine / metabolism. Indoles / pharmacology. Mice. Mice, Inbred ICR. Rats. Receptors, Prostaglandin / metabolism. p-Methoxy-N-methylphenethylamine / pharmacology

  • MedlinePlus Health Information. consumer health - Itching.
  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505747.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Imidazoles; 0 / Indoles; 0 / MK-0524; 0 / Receptors, Prostaglandin; 0 / Thiophenes; 0 / prostanoid D receptor 1, mouse; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 72W71I16EG / sertaconazole; 820484N8I3 / Histamine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


Advertisement
4. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V: Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther; 2009 Sep;8(9):2708-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
  • The urokinase-type plasminogen activator receptor (uPAR) plays a central role in sustaining the malignant phenotype and promoting tumor metastasis.
  • Here, we describe the generation of new peptide inhibitors of cell migration and invasion derived from SRSRY by a drug design approach.
  • Fluorescein-RERF associates with very high affinity to RBL-2H3 rat basophilic leukemia cells expressing the human formyl peptide receptor (FPR).
  • The involvement of vitronectin receptor is further supported by the findings that 100 pmol/L RERF selectively inhibits vitronectin-dependent RBL-2H3 cell migration and prevents SRSRY-triggered uPAR/alphav association.
  • Our findings indicate that RERF effectively prevents malignant cell invasion in vivo with no signs of toxicity and may represent a promising prototype drug for anticancer therapy.
  • [MeSH-major] Cell Movement / drug effects. Lung Neoplasms / secondary. Neoplasm Metastasis / prevention & control. Peptide Fragments / pharmacology. Receptors, Urokinase Plasminogen Activator / chemistry

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706734.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Receptors, Urokinase Plasminogen Activator
  •  go-up   go-down


5. Yang W, Chen J, Zhou L: Effects of shear stress on intracellular calcium change and histamine release in rat basophilic leukemia (RBL-2H3) cells. J Environ Pathol Toxicol Oncol; 2009;28(3):223-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of shear stress on intracellular calcium change and histamine release in rat basophilic leukemia (RBL-2H3) cells.
  • Massage, one form of physical therapy, is widely used for a large number of musculoskeletal disorders, but its exact mechanism still remains to be elucidated.
  • One hypothesis is that the shear stress caused by massage may induce cutaneous mast cells to release histamine, thereby improving the local tissue microcirculation of blood.
  • In the present work, a mast cell line (rat basophilic leukemia cells, RBL-2H3) was used in vitro to study cellular responses to the stimulus of shear stress generated by a rotating rotor in a cell dish.
  • Because histamine is a well-known mediator of microvascular tissue dilation, these results may have an important impact on understanding the mechanism involved in massage therapy.
  • [MeSH-minor] Animals. Calcium Channels / drug effects. Calcium Channels / physiology. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Indicators and Reagents / pharmacology. Leukemia, Basophilic, Acute. Microcirculation. Rats. Ruthenium Red / pharmacology. Stress, Mechanical. TRPV Cation Channels / antagonists & inhibitors. TRPV Cation Channels / metabolism

  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888909.001).
  • [ISSN] 2162-6537
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Indicators and Reagents; 0 / TRPV Cation Channels; 0 / Trpv4 protein, rat; 11103-72-3 / Ruthenium Red; 820484N8I3 / Histamine; SY7Q814VUP / Calcium
  •  go-up   go-down


6. Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, Blakely RD: Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. J Pharmacol Exp Ther; 2007 Jul;322(1):332-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using rat basophilic leukemia 2H3 cell line (RBL-2H3), we previously established that activation of A(3) adenosine receptors (A(3)AR) stimulates SERT activity via both PKG and p38 MAPK (Zhu et al., 2004a).
  • As in RBL-2H3 cells, IB-MECA stimulation of synaptosomal 5-HT uptake can be blocked by preincubation with PKG antagonists N-[2-(methylamino)ethy]-5-isoquinoline-sulfonamide (H8) and DT-2 (YGRKKRRQRRRPPLRK(5)H), as well as by the p38 MAPK inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole].
  • Chronoamperometry studies in the anesthetized rat hippocampus support a role for A(3)ARs in SERT regulation in vivo.
  • Together, these results identify a novel, region-specific action of CNS A(3)ARs in the modulation of SERT-mediated 5-HT transport that may be relevant for the etiology and/or therapy of 5-HT-linked brain disorders.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Adenosine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460150.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA07390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Adenosine A3; 0 / Serotonin Plasma Membrane Transport Proteins; 152918-18-8 / N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; 20125-40-0 / N-(1-methyl-2-phenylethyl)adenosine; 333DO1RDJY / Serotonin; 35920-39-9 / Adenosine-5'-(N-ethylcarboxamide); EC 2.7.11.12 / Cyclic GMP-Dependent Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; K72T3FS567 / Adenosine
  •  go-up   go-down


7. Kamiya S, Kawaguchi T, Hasebe S, Kamiya N, Saito Y, Miura S, Wada S, Yajima H, Katayama T, Fukai F: A fibronectin fragment induces tumor necrosis factor production of rat basophilic leukemia cells. Biochim Biophys Acta; 2004 Nov 18;1675(1-3):87-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fibronectin fragment induces tumor necrosis factor production of rat basophilic leukemia cells.
  • Proteolytic digest of fibronectin (FN), but not intact FN, induced TNF-alpha secretion of rat basophilic leukemia (RBL-2H3) cells.
  • The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides.
  • FNIII14 suppressed the spreading of RBL-2H3 cells on FN substrate, wherein RBL-2H3 cell proliferation was inhibited with FNIII14 in a dose-dependent manner.
  • Thus, it appears that FN fragments containing the YTIYVIAL anti-adhesive site affect the activation status of RBL-2H3 mast cells, characterized by the stimulation of TNF-alpha production and growth suppression, probably due to negative regulation of beta1 integrin activity.
  • [MeSH-major] Fibronectins / pharmacology. Leukemia, Basophilic, Acute / drug therapy. Peptide Fragments / pharmacology. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Animals. Anti-Bacterial Agents / pharmacology. Antigens, CD29 / metabolism. Cell Adhesion / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Cycloheximide / pharmacology. Heparin / metabolism. Humans. Lipopolysaccharides / pharmacology. Polymyxin B / pharmacology. Protein Structure, Tertiary. Protein Synthesis Inhibitors / pharmacology. Rats. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15535971.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antigens, CD29; 0 / Fibronectins; 0 / Lipopolysaccharides; 0 / Peptide Fragments; 0 / Protein Synthesis Inhibitors; 0 / Tumor Necrosis Factor-alpha; 1404-26-8 / Polymyxin B; 9005-49-6 / Heparin; 98600C0908 / Cycloheximide
  •  go-up   go-down


8. Cui Y, Hou X, Chen J, Xie L, Yang L, Le Y: Sesamin inhibits bacterial formylpeptide-induced inflammatory responses in a murine air-pouch model and in THP-1 human monocytes. J Nutr; 2010 Feb;140(2):377-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, sesamin inhibited FPR-transfected rat basophilic leukemia cell [epitope-tagged human FPR (ETFR) cell] migration toward fMLF (P < 0.01).
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Chemotaxis, Leukocyte / drug effects. Dioxoles / pharmacology. Leukemic Infiltration / drug therapy. Lignans / pharmacology. Monocytes / drug effects. Plant Extracts / pharmacology. Sesamum / chemistry
  • [MeSH-minor] Animals. Bacteria / metabolism. Basophils / drug effects. Bucladesine. Calcium / metabolism. Cell Line. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Inflammation / chemically induced. Inflammation / drug therapy. Inflammation / metabolism. Leukemia / drug therapy. Mice. Mice, Inbred C57BL. Mitogen-Activated Protein Kinase 1 / metabolism. Models, Animal. N-Formylmethionine Leucyl-Phenylalanine. NF-kappa B / antagonists & inhibitors. Phosphorylation. Phytotherapy. Rats. Receptors, Formyl Peptide / metabolism. Signal Transduction / drug effects

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032476.001).
  • [ISSN] 1541-6100
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Dioxoles; 0 / Lignans; 0 / NF-kappa B; 0 / Plant Extracts; 0 / Receptors, Formyl Peptide; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; 63X7MBT2LQ / Bucladesine; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; S7946O4P76 / sesamin; SY7Q814VUP / Calcium
  •  go-up   go-down


9. Liao BC, Hou RC, Wang JS, Jeng KC: Enhancement of the release of inflammatory mediators by substance P in rat basophilic leukemia RBL-2H3 cells. J Biomed Sci; 2006 Sep;13(5):613-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of the release of inflammatory mediators by substance P in rat basophilic leukemia RBL-2H3 cells.
  • In this study, SP and dinitrophenyl-bovine serum albumin (DNP-BSA) were used to activate rat basophilic leukemia (RBL)-2H3 cells.
  • SP enhanced the allergen-activated ERK pathway in RBL-2H3 cells, and Rb1 effectively inhibited the ERK pathway activation.
  • [MeSH-major] Ginsenosides / therapeutic use. Inflammation Mediators / metabolism. Neurogenic Inflammation / drug therapy
  • [MeSH-minor] Animals. Anti-Allergic Agents / pharmacology. Anti-Allergic Agents / therapeutic use. Cell Line. MAP Kinase Signaling System / drug effects. Rats. Serum Albumin, Bovine / pharmacology. Signal Transduction / drug effects. Substance P / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847722.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Ginsenosides; 0 / Inflammation Mediators; 0 / Serum Albumin, Bovine; 33507-63-0 / Substance P; 88140-34-5 / ginsenoside Rb1, malonyl
  •  go-up   go-down


10. Abe M, Shibata K, Urata H, Sakata N, Katsuragi T: Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone. J Cell Physiol; 2003 Jul;196(1):154-64
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone.
  • LTC(4) S activity in rat basophilic leukemia-1 (RBL-1) cells increased after culture in the presence of retinoic acid (RA) analogues, which was inhibited by cycloheximide or actinomycin D (ACD).
  • The suppression of LTC(4) S with MP showed a dependent manner on the time-point and duration of MP-treatment after RA-addition which was correlated with reduction in LTC(4) S mRNA and protein.
  • In consideration of RA-differentiation therapy, it may be of pathophysiological relevance that the antineoplastic agents potentiate RA-induced, steroid-sensitive, induction of LTC(4) S in RBL-1 cells.
  • [MeSH-major] Cell Differentiation / drug effects. Dactinomycin / antagonists & inhibitors. Dactinomycin / pharmacology. Glutathione Transferase / biosynthesis. Leukemia, Basophilic, Acute / enzymology. Methylprednisolone / pharmacology. Tretinoin / pharmacology
  • [MeSH-minor] Animals. Calcimycin / pharmacology. Cell Line. Cell Size / drug effects. Chymases. Cycloheximide / pharmacology. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Histamine / metabolism. Interleukin-4 / genetics. Lipoxygenase / metabolism. RNA Stability / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Serine Endopeptidases / metabolism. Solubility. Time Factors. Transcription, Genetic / drug effects

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12767051.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 1CC1JFE158 / Dactinomycin; 207137-56-2 / Interleukin-4; 37H9VM9WZL / Calcimycin; 5688UTC01R / Tretinoin; 820484N8I3 / Histamine; 98600C0908 / Cycloheximide; EC 1.13.11.12 / Lipoxygenase; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / Chymases; EC 4.4.1.20 / leukotriene-C4 synthase; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


11. Qu X, Li Y, Liu J, Xu L, Zhang Y, Hu X, Hou K, Liu Y: Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation. Mol Cell Biochem; 2010 Jul;340(1-2):107-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.
  • The ubiquitin ligase Cbl-b is a negative regulator of the PI3K/Akt pathway, the survival pathway implicated in chemotherapy resistance.
  • In this study, VP-16-induced RBL-2H3 cells apoptosis was accompanied by the activation of Akt and ERK.
  • The consistent results were also showed in the process of Ara-c treatment.
  • These observations indicate that Cbl-b promotes RBL-2H3 apoptosis induced by VP-16 or Ara-c, probably through inhibition of Akt and activation of ERK.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Leukemia, Basophilic, Acute / enzymology. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-cbl / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Cytarabine / pharmacology. Dose-Response Relationship, Drug. Enzyme Activation. Enzyme Inhibitors / pharmacology. Etoposide / pharmacology. Inhibitory Concentration 50. Mutation. Rats. Time Factors. Transfection

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Nov 1;177(9):5980-9 [17056522.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1779-86 [14604964.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):211-6 [10646608.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1921-30 [17581609.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1203-11 [17283156.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2367-77 [7784085.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4872-8 [11087752.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5331-9 [18832689.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1022-4 [17475912.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 29;367 (1):183-9 [18164258.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6271-80 [18676851.001]
  • [Cites] Eur J Haematol. 2003 Apr;70(4):219-24 [12656744.001]
  • [Cites] FEBS Lett. 2009 Jul 7;583(13):2255-62 [19508871.001]
  • [Cites] J Pathol. 2009 Jun;218(2):248-55 [19274672.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31498-507 [16014620.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):677-86 [15916691.001]
  • [Cites] Biochim Biophys Acta. 2006 Sep;1763(9):958-68 [16905201.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1423-33 [11857085.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10 ):3141-9 [18852117.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):870-5 [11526404.001]
  • [Cites] Immunity. 2007 May;26(5):567-78 [17493844.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):216-20 [10646609.001]
  • [Cites] Mutagenesis. 2006 Mar;21(2):105-14 [16500949.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Aug 24;213(3):837-44 [7654245.001]
  • [Cites] Neoplasia. 2008 Oct;10 (10 ):1083-91 [18813358.001]
  • (PMID = 20177738.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.3.2.27 / Proto-Oncogene Proteins c-cbl; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 6.3.2.19 / Cblb protein, rat
  •  go-up   go-down


12. Kobayashi S, Tanabe S: Evaluation of the anti-allergic activity of Citrus unshiu using rat basophilic leukemia RBL-2H3 cells as well as basophils of patients with seasonal allergic rhinitis to pollen. Int J Mol Med; 2006 Mar;17(3):511-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the anti-allergic activity of Citrus unshiu using rat basophilic leukemia RBL-2H3 cells as well as basophils of patients with seasonal allergic rhinitis to pollen.
  • To examine this anti-allergic mechanism in detail, we next used rat basophlilic leukemia RBL-2H3 cells.
  • MEC significantly inhibited IgE-induced histamine and beta-hexosaminidase release from RBL-2H3 cells.
  • [MeSH-major] Anti-Allergic Agents / therapeutic use. Basophils / drug effects. Citrus. Leukemia, Basophilic, Acute / immunology. Phytotherapy. Pollen / immunology. Rhinitis, Allergic, Seasonal / drug therapy
  • [MeSH-minor] Animals. Cell Degranulation / drug effects. Flavonoids / chemistry. Flavonoids / pharmacology. Flavonoids / therapeutic use. Histamine Release / drug effects. Humans. Immunoglobulin E / metabolism. Phosphatidylinositol 3-Kinases. Phosphorylation / drug effects. Plant Preparations / pharmacology. Plant Preparations / therapeutic use. Proto-Oncogene Proteins c-akt / metabolism. Rats. beta-N-Acetylhexosaminidases / secretion

  • Genetic Alliance. consumer health - Allergic rhinitis.
  • MedlinePlus Health Information. consumer health - Hay Fever.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465400.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Flavonoids; 0 / Plant Preparations; 37341-29-0 / Immunoglobulin E; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


13. Li Y, Lee SH, Le QT, Kim MM, Kim SK: Anti-allergic effects of phlorotannins on histamine release via binding inhibition between IgE and Fc epsilonRI. J Agric Food Chem; 2008 Dec 24;56(24):12073-80
MedlinePlus Health Information. consumer health - Allergy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, anti-allergic activities of phloroglucinol derivatives were assessed on human basophilic leukemia (KU812) and rat basophilic leukemia (RBL-2H3) cell lines using a histamine release assay.
  • These results suggested that compounds 1 and 3 could be the key effectors in the crude methanol extract of EC against allergy disease and used as novel candidates for development in the cosmetic and drug industries potentially.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Histamine Release / drug effects. Hypersensitivity / drug therapy. Immunoglobulin E / immunology. Phaeophyta / chemistry. Phloroglucinol / pharmacology. Plant Extracts / pharmacology. Receptors, IgE / immunology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Protein Binding / drug effects. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053379.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Plant Extracts; 0 / Receptors, IgE; 37341-29-0 / Immunoglobulin E; DHD7FFG6YS / Phloroglucinol
  •  go-up   go-down


14. Baumann MJ, Eggel A, Amstutz P, Stadler BM, Vogel M: DARPins against a functional IgE epitope. Immunol Lett; 2010 Oct 30;133(2):78-84
Hazardous Substances Data Bank. Omalizumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The monoclonal anti-IgE antibody omalizumab (Xolair is mostly used for the treatment of severe allergic asthma.
  • However, the requirement of high doses and suboptimal cost-effectiveness limits the use of the treatment.
  • Here we propose to use a new drug format based on non-immunoglobulin structures, potentially offering increased clinical efficacy while being more cost-effective.
  • Furthermore, anti-IgE DARPins were shown to inhibit proinflammatory mediator release from rat basophilic leukemia cells expressing human high-affinity IgE receptors with higher efficacy than the monoclonal anti-IgE antibody omalizumab.
  • DARPins may thus represent promising future drug candidates for the treatment of allergy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Asthma / drug therapy. Epitopes, B-Lymphocyte / immunology. Immunoglobulin E / metabolism. Recombinant Fusion Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20673836.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / DARPin E2 79; 0 / Epitopes, B-Lymphocyte; 0 / Immunoglobulin Constant Regions; 0 / Recombinant Fusion Proteins; 2P471X1Z11 / Omalizumab; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


15. Zhu J, Wang O, Ruan L, Hou X, Cui Y, Wang JM, Le Y: The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR. Int Immunopharmacol; 2009 Aug;9(9):1126-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment of human monocytic cells or FPR-transfected rat basophilic leukemia cells (ETFR cells) with EGCG significantly inhibited fMLF-induced chemotaxis.
  • [MeSH-minor] Animals. Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors. Camellia sinensis / immunology. Cell Line, Tumor. Cell Movement / drug effects. Cell Movement / immunology. Flavonoids / pharmacology. Humans. Inflammation. Injections, Intraperitoneal. Leukemia, Basophilic, Acute / blood. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / immunology. Mice. Rats. Receptors, Formyl Peptide / genetics. Receptors, Formyl Peptide / immunology. Receptors, Formyl Peptide / metabolism. Signal Transduction / drug effects. Signal Transduction / immunology. Transfection. Transgenes

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19426837.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antioxidants; 0 / Flavonoids; 0 / Receptors, Formyl Peptide; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


16. Cho YS, Kim CH, Surh JH, Kang NS, Yoo SE, Cheon HG: Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl-phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity. Pharmacology; 2010;86(2):65-72
Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 5-LO enzyme activity was assayed using insect cell lysates overexpressing rat 5-LO.
  • The leukotriene B(4) (LTB(4)) level was assayed in rat basophilic leukemia (RBL-1) cell line.
  • RESULTS: KR-33749 inhibited 5-LO activity with an IC(50) value of 70.5 +/- 6.0 nmol/l in parallel with LTB(4) inhibition in RBL-1 cells.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Arachidonate 5-Lipoxygenase / metabolism. Lipoxygenase Inhibitors / pharmacology. Lipoxygenase Inhibitors / therapeutic use. Thiazoles / pharmacology. Thiazoles / therapeutic use. Xylenes / pharmacology. Xylenes / therapeutic use
  • [MeSH-minor] Animals. Arachidonic Acid / toxicity. Cell Line, Tumor. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / immunology. Dermatitis, Atopic / pathology. Dinitrochlorobenzene / toxicity. Dose-Response Relationship, Drug. Edema / prevention & control. Isoenzymes / antagonists & inhibitors. Leukotriene B4 / metabolism. Leukotriene B4 / secretion. Male. Mice. Mice, Inbred BALB C. Osmolar Concentration. Rats. Recombinant Proteins / antagonists & inhibitors. Skin / drug effects. Skin / pathology. Skin Diseases / drug therapy. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20639685.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 4-(4-(4-fluorophenyl)thiazol-2-ylamino)-2,6-dimethylphenol; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Isoenzymes; 0 / Lipoxygenase Inhibitors; 0 / Recombinant Proteins; 0 / Thiazoles; 0 / Xylenes; 1HGW4DR56D / Leukotriene B4; 27YG812J1I / Arachidonic Acid; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


17. Li L, Ji H, Sheng L, Zhang Y, Lai Y, Chen X: The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol; 2009 Apr 1;607(1-3):244-50
Hazardous Substances Data Bank. CARRAGEENAN GUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It also inhibited the production of thromboxane B(2) and prostaglandin E(2) in calcium ionophore A23187-induced human (IC(50)=0.50 microM) and rat whole blood (IC(50)=0.93 microM), and rat peritoneal leukocytes (IC(50)=2.27 microM).
  • ZLJ-6 suppressed the activity of 5-lipoxygenase in the rat basophilic leukemia (RBL-1) cell lysate (IC(50)=0.32 microM) and in intact cells (IC(50)=1.06 microM) and reduced the generation of leukotriene B(4) (LTB(4)) in A23187-stimulated human (IC(50)=1.61 microM) or rat whole blood (IC(50)=0.99 microM), and rat peritoneal leukocytes (IC(50)=2.59 microM).
  • Thus ZLJ-6 is an ideal substitute for classical non-steroidal anti-inflammatory therapy.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Cyclooxygenase Inhibitors / pharmacology. Edema / drug therapy. Imidazoles / pharmacology. Sulfones / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. Carrageenan. Cyclooxygenase 1 / drug effects. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / drug effects. Cyclooxygenase 2 / metabolism. Dinoprostone / antagonists & inhibitors. Disease Models, Animal. Female. Humans. Inhibitory Concentration 50. Leukocytes / drug effects. Leukocytes / metabolism. Leukotriene B4 / antagonists & inhibitors. Lipoxygenase Inhibitors / administration & dosage. Lipoxygenase Inhibitors / pharmacology. Lipoxygenase Inhibitors / toxicity. Male. Rats. Rats, Sprague-Dawley. Thromboxane B2 / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243697.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 1-methyl-1,5-dihydro-2-amino-5-(4-(mesyl)benzylidene)-4H-imidazole-4-one; 0 / Anti-Inflammatory Agents; 0 / Cyclooxygenase Inhibitors; 0 / Imidazoles; 0 / Lipoxygenase Inhibitors; 0 / Sulfones; 1HGW4DR56D / Leukotriene B4; 54397-85-2 / Thromboxane B2; 9000-07-1 / Carrageenan; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


18. Sakai S, Sugawara T, Kishi T, Yanagimoto K, Hirata T: Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci; 2010 Feb 27;86(9-10):337-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN METHODS: Dinitrophenyl (DNP)-IgE-sensitized rat basophilic leukemia RBL-2H3 cells were treated with glucosamine-HCl (GlcN-HCl), N-acetylglucosamine (GlcNAc), chitin oligomer or chitosan oligomer.
  • KEY FINDINGS: GlcN-HCl significantly inhibited the antigen-induced degranulation of RBL-2H3 cells at higher than 0.01 mg/mL for 24h-treatment while GlcNAc, a chitin oligomer and a chitosan oligomer had no effect.
  • [MeSH-major] Cell Degranulation / physiology. Dinitrofluorobenzene / toxicity. Ear. Edema / drug therapy. Glucosamine / therapeutic use. Mast Cells / physiology

  • MedlinePlus Health Information. consumer health - Edema.
  • Hazardous Substances Data Bank. GLUCOSAMINE .
  • Hazardous Substances Data Bank. 1-FLUORO-2,4-DINITROBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20093129.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] D241E059U6 / Dinitrofluorobenzene; N08U5BOQ1K / Glucosamine
  •  go-up   go-down


19. Di Marzo V, Melck D, De Petrocellis L, Bisogno T: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat; 2000 Apr;61(1-2):43-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biosynthesis of AEA, PEA, or 2-AG can be induced by stimulation with either Ca(2+) ionophores, lipopolysaccharide, or platelet activating factor in macrophages, and by ionomycin or antigen challenge in rat basophilic leukemia (RBL-2H3) cells (a widely used model for mast cells).
  • AEA and PEA modulate cytokine and/or arachidonate release from macrophages in vitro, regulate serotonin secretion from RBL-2H3 cells, and are analgesic in some animal models of inflammatory pain.
  • [MeSH-minor] Adjuvants, Immunologic / metabolism. Adjuvants, Immunologic / pharmacology. Animals. Anti-Inflammatory Agents, Non-Steroidal / chemistry. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Cannabinoids / metabolism. Cell Division / drug effects. Endocannabinoids. Ethanolamines. Humans. Male. Polyunsaturated Alkamides. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Rats. Receptors, Growth Factor / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10785541.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Arachidonic Acids; 0 / Cannabinoids; 0 / Endocannabinoids; 0 / Ethanolamines; 0 / Glycerides; 0 / Palmitic Acids; 0 / Polyunsaturated Alkamides; 0 / Receptors, Growth Factor; 53847-30-6 / 2-arachidonylglycerol; 6R8T1UDM3V / palmidrol; 94421-68-8 / anandamide
  • [Number-of-references] 99
  •  go-up   go-down


20. Lee JY, Jang YW, Kang HS, Moon H, Sim SS, Kim CJ: Anti-inflammatory action of phenolic compounds from Gastrodia elata root. Arch Pharm Res; 2006 Oct;29(10):849-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous screening of the pharmacological action of Gastrodia elata (GE) root (Orchidaceae) showed that methanol (MeOH) extracts have significant anti-inflammatory properties.
  • To investigate the anti-inflammatory and anti-oxidant activity of these compounds, their effects on carrageenan-induced paw edema, arachidonic acid (AA)-induced ear edema and analgesic activity in acetic acid (HAc)-induced writhing response were carried out in vivo; cyclooxygenase (COX) activity, reactive oxygen species (ROS) generation in rat basophilic leukemia (RBL 2H3) cells and 1,1-diphenyl-2-picryl-hydroazyl (DPPH) scavenging activity were determined in vitro.
  • [MeSH-minor] Acetic Acid. Animals. Anti-Inflammatory Agents / chemistry. Anti-Inflammatory Agents / pharmacology. Arachidonic Acid. Benzyl Compounds / chemistry. Benzyl Compounds / pharmacology. Carrageenan. Dose-Response Relationship, Drug. Ear, External / drug effects. Ear, External / pathology. Edema / chemically induced. Edema / drug therapy. Hindlimb / drug effects. Hindlimb / pathology. Inflammation / chemically induced. Inflammation / prevention & control. Male. Methanol. Molecular Structure. Pain / chemically induced. Pain / drug therapy. Plant Extracts / chemistry. Plant Extracts / pharmacology. Prostaglandin-Endoperoxide Synthases / metabolism. Quantitative Structure-Activity Relationship. Rats. Rats, Sprague-Dawley. Reactive Oxygen Species / antagonists & inhibitors. Reactive Oxygen Species / metabolism

  • Hazardous Substances Data Bank. ACETIC ACID .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121179.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Benzyl Compounds; 0 / Cyclooxygenase Inhibitors; 0 / Phenols; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 27YG812J1I / Arachidonic Acid; 9000-07-1 / Carrageenan; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; Q40Q9N063P / Acetic Acid; Y4S76JWI15 / Methanol
  •  go-up   go-down


21. Song Y, Qu C, Srivastava K, Yang N, Busse P, Zhao W, Li XM: Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils. J Allergy Clin Immunol; 2010 Dec;126(6):1208-17.e3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Direct effects of FAHF-2 on the murine mast cell line MC/9, and effects of 4 fractions and 3 compounds isolated from FAHF-2 on rat basophilic leukemia cells (RBL-2H3) and human skin mast cells degranulation and on the IgE-mediated spleen tyrosine kinase signaling pathway, were determined.
  • RESULTS: Although all sham-treated PNA mice developed anaphylaxis, FAHF-2-treated PNA mice were protected against anaphylaxis after peanut challenge at 1 day and 4 weeks posttherapy.
  • Reduction of peripheral blood basophils began after 1 week of treatment and continued for at least 4 weeks posttherapy.
  • Fraction 2 from FAHF-2 inhibited RBL-2H3 cell and human mast cell degranulation.
  • Three compounds from fraction 2-berberine, palmatine, and jatrorrhizine-inhibited RBL-2H3 cell degranulation via suppressing spleen tyrosine kinase phosphorylation.

  • MedlinePlus Health Information. consumer health - Food Allergy.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):32-9 [10608502.001]
  • [Cites] Biochem Biophys Res Commun. 2010 May 14;395(4):547-52 [20394728.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1616-7 [10979667.001]
  • [Cites] APMIS. 2000 Oct;108(10):633-41 [11200817.001]
  • [Cites] J Allergy Clin Immunol. 2001 Jun;107(6):1077-81 [11398088.001]
  • [Cites] Immunity. 2001 Jun;14(6):791-800 [11420048.001]
  • [Cites] Immunity. 2001 Jun;14(6):801-11 [11420049.001]
  • [Cites] J Allergy Clin Immunol. 2001 Aug;108(2 Suppl):S84-8 [11498678.001]
  • [Cites] J Allergy Clin Immunol. 2001 Oct;108(4):639-46 [11590394.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jul;110(1):117-24 [12110830.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):773-86 [12360215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12911-6 [14569021.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4317-23 [15383560.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):663-72 [9034145.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2517-21 [9058781.001]
  • [Cites] J Allergy Clin Immunol. 2005 Jan;115(1):171-8 [15637565.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2635-42 [16081839.001]
  • [Cites] Clin Exp Allergy. 2007 May;37(5):651-60 [17456212.001]
  • [Cites] Clin Exp Allergy. 2007 Jun;37(6):846-55 [17517098.001]
  • [Cites] Clin Exp Allergy. 2007 Sep;37(9):1392-403 [17845421.001]
  • [Cites] J Med Food. 2008 Mar;11(1):14-20 [18361733.001]
  • [Cites] Phytother Res. 2008 May;22(5):651-9 [18389474.001]
  • [Cites] J Agric Food Chem. 2008 Dec 24;56(24):12073-80 [19053379.001]
  • [Cites] J Allergy Clin Immunol. 2009 Feb;123(2):443-51 [19203662.001]
  • [Cites] Food Chem Toxicol. 2009 Jul;47(7):1659-66 [19394399.001]
  • [Cites] Inflamm Res. 2009 Sep;58(9):611-8 [19301096.001]
  • [Cites] Curr Opin Hematol. 2010 Jan;17(1):60-6 [19741522.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):150-8 [10887318.001]
  • (PMID = 21134573.001).
  • [ISSN] 1097-6825
  • [Journal-full-title] The Journal of allergy and clinical immunology
  • [ISO-abbreviation] J. Allergy Clin. Immunol.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / AT001495-05A1; United States / NCCIH NIH HHS / AT / R01 AT001495; United States / NCCIH NIH HHS / AT / R01 AT001495-05A1; United States / NCCIH NIH HHS / AT / AT001495-01A1; United States / NCCIH NIH HHS / AT / 2 R01 AT001495-05A1; United States / NCCIH NIH HHS / AT / R01 AT001495-01A1; United States / NCCIH NIH HHS / AT / 1R01AT001495-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Food Allergy Herbal Formula-2; 0 / Plant Extracts; 0 / Receptors, IgE; 37341-29-0 / Immunoglobulin E
  • [Other-IDs] NLM/ NIHMS248602; NLM/ PMC3059770
  •  go-up   go-down


22. Chan JH, Liao W, Lau HY, Wong WS: Gab2 antisense oligonucleotide blocks rat basophilic leukemic cell functions. Int Immunopharmacol; 2007 Jul;7(7):937-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gab2 antisense oligonucleotide blocks rat basophilic leukemic cell functions.
  • The present study aimed to investigate the pharmacological effects of an antisense oligonucleotide (ASO) targeted at Gab2 on the immune responses of rat basophilic leukemic (RBL)-2H3 cells.
  • Gab2 ASOs were rationally designed and transfected into RBL-2H3 cells.
  • Gab2 mRNA and protein knockdown was confirmed by real-time RT-PCR and immunoblotting, respectively.
  • We have characterized a phosphorothioate-modified ASO targeted at Gab2 mRNA that was able to knockdown Gab2 mRNA and protein in RBL-2H3 cells.
  • In addition, Gab2 ASO markedly prevented mast cell adhesion to fibronectin-coated plates and restrained random migration of RBL-2H3 cells in cell culture chambers.
  • Our findings show that Gab2 knockdown in RBL-2H3 cells by ASO strategy can suppress many aspects of the mast cell functions and, therefore, a selective Gab2 ASO may have therapeutic potential for mast cell-dependent allergic disorders.
  • [MeSH-major] Basophils / immunology. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / immunology. Oligonucleotides, Antisense / pharmacology. Phosphoproteins / genetics. RNA, Messenger / metabolism. Signal Transduction / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499196.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Fibronectins; 0 / Gab2 protein, rat; 0 / Oligonucleotides, Antisense; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / Receptors, IgE; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


23. Beck MN, Balmer A, Dessing C, Pica A, Munier F: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol; 2000 Aug;18(15):2881-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma.
  • PURPOSE: To evaluate the efficacy of first-line chemotherapy (CT) in preventing external-beam radiotherapy (EBR) and/or enucleation in patients with retinoblastoma (Rbl).
  • PATIENTS AND METHODS: Twenty-four patients with newly diagnosed unilateral or bilateral Rbl received CT associated with local treatment (LT).
  • Two to five courses of etoposide and carboplatin were administered at 3- to 4-week intervals, depending on tumor response, and were completed each time by LT.
  • Six other patients with advanced disease (groups IV and V) experienced treatment failure and needed salvage treatment by EBR and/or enucleation.
  • CONCLUSION: CT combined with intensive LT is effective in patients with groups I to III Rbl, permitting the avoidance of EBR in the majority of these young children and, thus, reducing the risk of long-term sequelae.
  • This is in contrast with the disappointing results for patients with groups IV and V Rbl, in whom EBR and/or enucleation was needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eye Enucleation. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2001 Nov 1;19(21):4182-3 [11689590.001]
  • (PMID = 10920136.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Liu X, Groschner K, Ambudkar IS: Distinct Ca(2+)-permeable cation currents are activated by internal Ca(2+)-store depletion in RBL-2H3 cells and human salivary gland cells, HSG and HSY. J Membr Biol; 2004 Jul 15;200(2):93-104
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct Ca(2+)-permeable cation currents are activated by internal Ca(2+)-store depletion in RBL-2H3 cells and human salivary gland cells, HSG and HSY.
  • Here we have compared the properties of SOC currents ( I(SOC)) in human submandibular glands cells (HSG) and human parotid gland cells (HSY) with I(CRAC) (Ca(2+) release-activated Ca(2+) current) in RBL cells.
  • Internal Ca(2+) store-depletion with IP(3) or thapsigargin activated cation channels in all three cell types.
  • Washout of Gd(3+) induced partial recovery in HSY and HSG but not RBL cells.
  • I(CRAC )in RBL cells displayed strong inward rectification with E(rev)(Ca) = >+90 mV and E(rev) (Na) = +60 mV.
  • HSY cells displayed a linear current with E(rev) = +5 mV, which was similar in Ca(2+)- or Na(+)-containing medium. pCa/ pNa was >500, 40, and 4.6 while pCs / pNa was 0.1,1, and 1.3, for RBL, HSG, and HSY cells, respectively.
  • Evidence for anomalous mole fraction behavior of Ca(2+)/Na(+) permeation was obtained with RBL and HSG cells but not HSY cells.
  • Additionally, channel inactivation with Ca(2+) + Na(+) or Na(+) in the bath was different in the three cell types.
  • In aggregate, these data demonstrate that distinct store-dependent cation currents are stimulated in RBL, HSG, and HSY cells.
  • [MeSH-minor] Cadmium / pharmacology. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cations / metabolism. Cell Line. Enzyme Inhibitors / pharmacology. Humans. Inositol 1,4,5-Trisphosphate / pharmacology. Ion Channel Gating / drug effects. Membrane Potentials / drug effects. Patch-Clamp Techniques. Sarcoplasmic Reticulum / metabolism. Thapsigargin / pharmacology

  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1999 Jul 15;518 Pt 2:345-58 [10381584.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:521-55 [11031246.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3403-11 [10652333.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):323-36 [12765679.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 1):C571-80 [9688612.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1415-59 [11581493.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):E263-72 [12415286.001]
  • [Cites] Pflugers Arch. 2002 Mar;443(5-6):892-902 [11889590.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11337-43 [12536150.001]
  • [Cites] J Gen Physiol. 2002 May;119(5):487-507 [11981025.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27799-805 [10882720.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21649-54 [12686562.001]
  • [Cites] Hepatology. 2001 Apr;33(4):938-47 [11283858.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40088-96 [12874277.001]
  • [Cites] Endocr Rev. 1993 Oct;14(5):610-31 [8262009.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):433-40 [12765688.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33295-304 [9837902.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33704-10 [12093812.001]
  • [Cites] Crit Rev Oral Biol Med. 2000;11(1):4-25 [10682899.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):451-61 [12765690.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):379-91 [12543097.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26158-63 [10851243.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26950-8 [12011062.001]
  • [Cites] Biochem Soc Trans. 2003 Oct;31(Pt 5):925-9 [14505450.001]
  • [Cites] J Physiol. 2003 Mar 1;547(Pt 2):333-48 [12576497.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):345-56 [12765681.001]
  • [Cites] Neuron. 2001 Mar;29(3):645-55 [11301024.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):121-7 [11175743.001]
  • [Cites] Nature. 1992 Jan 23;355(6358):353-6 [1309940.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21617-23 [11943785.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):311-21 [12765678.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14925-32 [9614097.001]
  • [Cites] J Membr Biol. 2001 Jun 1;181(3):185-93 [11420605.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):901-30 [9354808.001]
  • [Cites] Mol Cell. 2002 Apr;9(4):739-50 [11983166.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):29891-8 [11395504.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21 [11413485.001]
  • [Cites] Bioessays. 1999 Jan;21(1):38-46 [10070252.001]
  • [Cites] Curr Opin Neurobiol. 2003 Jun;13(3):298-307 [12850214.001]
  • (PMID = 15520907.001).
  • [ISSN] 0022-2631
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Cations; 0 / Enzyme Inhibitors; 00BH33GNGH / Cadmium; 67526-95-8 / Thapsigargin; 85166-31-0 / Inositol 1,4,5-Trisphosphate; SY7Q814VUP / Calcium
  •  go-up   go-down


25. Tries S, Neupert W, Laufer S: The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res; 2002 Mar;51(3):135-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We examined the effects of ML3000 and several non-steroidal antiinflammatory drugs (NSAIDs) on the synthesis of products of 5-LOX (LTB4, LTC4) and COX-1/2 (TXB2, PGE2) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.
  • 5-lipoxygenase inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells.
  • In carrageenan induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE2 in the inflamed tissue.
  • 5-LOX inhibition in the inflamed rat colon was investigated by measuring LTB4 synthesis.
  • MK-886 and ML3000 at 10 mg/kg p.o. reduced LTB4 production to 29.8 +/- 4.9 and 30.1 +/- 2.8 pg/mg tissue as compared to control (54.2 +/- 7.4 mg/kg tissue).
  • LTB4 levels in the rat stomach were comparable to control (2.5 +/- 0.4 pg/mg protein) after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB4 up to 9.2 +/- 2.3 or 8.9 +/- 1.6 pg/mg protein.
  • [MeSH-minor] Adult. Animals. Colon / drug effects. Colon / metabolism. Edema / drug therapy. Edema / metabolism. Humans. Leukotriene B4 / biosynthesis. Leukotriene C4 / biosynthesis. Male. Rats. Rats, Sprague-Dawley. Rats, Wistar. Stomach / drug effects. Stomach / metabolism. Thromboxane B2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12005204.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Acetates; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Pyrroles; 156897-06-2 / licofelone; 1HGW4DR56D / Leukotriene B4; 2CU6TT9V48 / Leukotriene C4; 54397-85-2 / Thromboxane B2
  •  go-up   go-down


26. Lee SH, Bae EA, Park EK, Shin YW, Baek NI, Han EJ, Chung HG, Kim DH: Inhibitory effect of eupatilin and jaceosidin isolated from Artemisia princeps in IgE-induced hypersensitivity. Int Immunopharmacol; 2007 Dec 15;7(13):1678-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These isolated components potently inhibited the release of beta-hexosaminidase from RBL-2H3 cells induced by the IgE-antigen complex, with IC(50) values of 3.4 and 4.5muM, respectively.
  • Eupatilin and jaceosidin inhibited the gene expressions of TNF-alpha and IL-4 in RBL-2H3 cells stimulated by IgE-antigen complex.
  • [MeSH-major] Artemisia / chemistry. Flavonoids / pharmacology. Hypersensitivity / drug therapy. Immunoglobulin E / immunology
  • [MeSH-minor] Animals. Cytokines / biosynthesis. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. NF-kappa B / metabolism. Passive Cutaneous Anaphylaxis / drug effects. beta-N-Acetylhexosaminidases / secretion

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996677.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Flavonoids; 0 / NF-kappa B; 18085-97-7 / jaceosidin; 37341-29-0 / Immunoglobulin E; 4D58O05490 / eupatilin; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


27. Lim H, Nam JW, Seo EK, Kim YS, Kim HP: (-)-Nyasol (cis-hinokiresinol), a norneolignan from the rhizomes of Anemarrhena asphodeloides, is a broad spectrum inhibitor of eicosanoid and nitric oxide production. Arch Pharm Res; 2009 Nov;32(11):1509-14
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess the anti-inflammatory activity of constituents from the rhizomes of Anemarrhena asphodeloides, (-)-nyasol {cis-hinokiresinol, 4,4-[1Z,3R]-3-ethenyl-1-propene-1,3-diyl]bisphenol} was isolated and its anti-inflammatory activity was examined in lipopolysaccharide (LPS)-treated RAW 264.7 cells and A23187-treated RBL-1 cells.
  • At > 1 microM, (-)-nyasol significantly inhibited cyclooxygenase-2 (COX-2)-mediated PGE2 production and inducible nitric oxide synthase (iNOS)-mediated NO production in LPS-treated RAW 264.7 cells, a mouse macrophage-like cell line, but did not affect the expression levels of COX-2 and iNOS. (-)-Nyasol also inhibited 5-lipoxygenase (5-LOX)-mediated leukotriene production in A23187-treated RBL-1 cells.
  • [MeSH-major] Anemarrhena / chemistry. Anti-Inflammatory Agents / pharmacology. Inflammation / drug therapy. Lignans / pharmacology. Phenols / pharmacology
  • [MeSH-minor] Animals. Cyclooxygenase 2 / drug effects. Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / administration & dosage. Cyclooxygenase 2 Inhibitors / isolation & purification. Cyclooxygenase 2 Inhibitors / pharmacology. Disease Models, Animal. Dose-Response Relationship, Drug. Eicosanoids / biosynthesis. Lipopolysaccharides. Lipoxygenase Inhibitors. Male. Mice. Mice, Inbred ICR. Nitric Oxide / biosynthesis. Nitric Oxide Synthase Type II / antagonists & inhibitors. Rats. Rhizome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20091263.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Eicosanoids; 0 / Lignans; 0 / Lipopolysaccharides; 0 / Lipoxygenase Inhibitors; 0 / Phenols; 31C4KY9ESH / Nitric Oxide; 96895-25-9 / nyasol; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


28. Han EH, Park JH, Kim JY, Jeong HG: Houttuynia cordata water extract suppresses anaphylactic reaction and IgE-mediated allergic response by inhibiting multiple steps of FcepsilonRI signaling in mast cells. Food Chem Toxicol; 2009 Jul;47(7):1659-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we investigated the effects of H. cordata water extract (HCWE) on passive cutaneous anaphylaxis (PCA) in mice and on IgE-mediated allergic response in rat mast RBL-2H3 cells.
  • HCWE also reduced antigen (DNP-BSA)-induced release of beta-hexosaminidase, histamine, and reactive oxygen species in IgE-sensitized RBL-2H3 cells.
  • In addition, HCWE inhibited antigen-induced IL-4 and TNF-alpha production and expression in IgE-sensitized RBL-2H3 cells.
  • Taken together, the in vivo/in vitro anti-allergic effect of HCWE suggests possible therapeutic applications of this agent in inflammatory allergic diseases through inhibition of cytokines and multiple events of FcepsilonRI-dependent signaling cascades in mast cells.
  • [MeSH-major] Anaphylaxis / drug therapy. Houttuynia / chemistry. Hypersensitivity / drug therapy. Immunoglobulin E / physiology. Mast Cells / immunology. Receptors, IgE / drug effects
  • [MeSH-minor] Animals. Blotting, Western. Cell Line. Cytokines / biosynthesis. Female. Hexosaminidase B / metabolism. Histamine Release / drug effects. Luciferases / genetics. Mice. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis / drug effects. Plant Extracts / pharmacology. RNA / biosynthesis. RNA / genetics. Rats. Reactive Oxygen Species / metabolism. Signal Transduction / drug effects. Solvents. Subcellular Fractions / drug effects. Subcellular Fractions / metabolism. Transfection. Water

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. Water .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394399.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / Receptors, IgE; 0 / Solvents; 059QF0KO0R / Water; 37341-29-0 / Immunoglobulin E; 63231-63-0 / RNA; EC 1.13.12.- / Luciferases; EC 3.2.1.52 / Hexosaminidase B
  •  go-up   go-down


29. Trinh HT, Shin YW, Han SJ, Han MJ, Kim DH: Evaluation of antipruritic effects of red ginseng and its ingredients in mice. Planta Med; 2008 Feb;74(3):210-4
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These ginsenosides also inhibited the expression of TNF-alpha and IL-4 induced by IgE-antigen complex in RBL-2H3 cells, as well as acetic acid-induced writhing in mice.
  • [MeSH-major] Antipruritics / analysis. Ginsenosides / therapeutic use. Panax / chemistry. Phytotherapy. Pruritus / drug therapy
  • [MeSH-minor] Acetic Acid. Animals. Histamine. Immunoglobulin E. Interleukin-4 / metabolism. Mice. Plant Extracts / therapeutic use. Plant Roots / chemistry. Rats. Tumor Necrosis Factor-alpha / metabolism. p-Methoxy-N-methylphenethylamine

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Itching.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300192.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipruritics; 0 / Ginsenosides; 0 / Plant Extracts; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 820484N8I3 / Histamine; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


30. Park EK, Sung JH, Trinh HT, Bae EA, Yun HK, Hong SS, Kim DH: Lactic acid bacterial fermentation increases the antiallergic effects of Ixeris dentata. J Microbiol Biotechnol; 2008 Feb;18(2):308-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fermentation of ID with Bifidobacterium breve or Lactobacillus acidophilus increased its inhibition of degranulation in RBL-2H3 cells induced by the IgE-antigen complex.
  • These extracts also inhibited mRNA expression of TNF-alpha and IL-4, as well as NF-kappaB activation in RBL-2H3 cells induced by the IgE-antigen complex.
  • [MeSH-major] Anti-Allergic Agents / administration & dosage. Asteraceae / metabolism. Bifidobacterium / metabolism. Fermentation. Hypersensitivity, Immediate / drug therapy. Lactobacillus acidophilus / metabolism. Plant Preparations / administration & dosage
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Cell Degranulation / drug effects. Cell Line, Tumor. Cytokines / antagonists & inhibitors. Cytokines / metabolism. Humans. Korea. Male. Mice. NF-kappa B / antagonists & inhibitors. NF-kappa B / genetics. Nitric Oxide / antagonists & inhibitors. Nitric Oxide / metabolism. Passive Cutaneous Anaphylaxis / drug effects. Rats. Transcriptional Activation / drug effects

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309276.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Cytokines; 0 / NF-kappa B; 0 / Plant Preparations; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


31. Han SJ, Bae EA, Trinh HT, Yang JH, Youn UJ, Bae KH, Kim DH: Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors. Biol Pharm Bull; 2007 Nov;30(11):2201-3
Hazardous Substances Data Bank. MAGNOLOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These constituents exhibited not only potent inhibitory activity on the degranulation of RBL-2H3 cells induced by IgE-antigen complex, with IC(50) values of 45 and 55 muM, respectively, but also inhibited the protein expressions of IL-4 and TNF-alpha.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Biphenyl Compounds / pharmacology. Lignans / pharmacology. Passive Cutaneous Anaphylaxis / drug effects. Pruritus / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Immunoglobulin E / immunology. Inhibitory Concentration 50. Male. Mast Cells / metabolism. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Molecular Structure. Rats. beta-N-Acetylhexosaminidases / secretion. p-Methoxy-N-methylphenethylamine / immunology

  • MedlinePlus Health Information. consumer health - Itching.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978501.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Biphenyl Compounds; 0 / Lignans; 001E35HGVF / magnolol; 11513CCO0N / honokiol; 37341-29-0 / Immunoglobulin E; 4091-50-3 / p-Methoxy-N-methylphenethylamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


32. Qin HD, Shi YQ, Liu ZH, Li ZG, Wang HS, Wang H, Liu ZP: Effect of chlorogenic acid on mast cell-dependent anaphylactic reaction. Int Immunopharmacol; 2010 Sep;10(9):1135-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, CGA dose-dependently reduced histamine and TNF-alpha release from RBL-2H3 cells activated by anti-DNP IgE.
  • Pretreatment with CGA suppressed IgE-antigen complex induced calcium uptake into RBL-2H3 cells.
  • When CGA was added, the level of intracellular cyclic adenosine monophosphate (cAMP) in RBL-2H3 cells was significantly elevated compared with the untreated cells.
  • These results suggest a possible therapeutic application of CGA in allergic diseases.
  • [MeSH-major] Anaphylaxis / drug therapy. Chlorogenic Acid / pharmacology. Mast Cells / drug effects
  • [MeSH-minor] Animals. Calcium / analysis. Calcium / immunology. Calcium Channels / drug effects. Calcium Channels / immunology. Capillary Permeability / drug effects. Capillary Permeability / immunology. Cells, Cultured. Cyclic AMP / analysis. Cyclic AMP / immunology. Dinitrophenols / toxicity. Histamine Release / drug effects. Histamine Release / immunology. Immunoglobulin E / analysis. Immunoglobulin E / immunology. Male. Mice. Mice, Inbred BALB C. Rats. Rats, Wistar. Skin / drug effects. Skin / immunology. Tumor Necrosis Factor-alpha / immunology. Tumor Necrosis Factor-alpha / secretion. p-Methoxy-N-methylphenethylamine / adverse effects. p-Methoxy-N-methylphenethylamine / immunology

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20620227.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Dinitrophenols; 0 / Tumor Necrosis Factor-alpha; 318ADP12RI / Chlorogenic Acid; 37341-29-0 / Immunoglobulin E; 4091-50-3 / p-Methoxy-N-methylphenethylamine; E0399OZS9N / Cyclic AMP; SY7Q814VUP / Calcium
  •  go-up   go-down


33. Lee SH, Shin YW, Bae EA, Lee B, Min S, Baek NI, Chung HG, Kim NJ, Kim DH: Lactic acid bacteria increase antiallergic effect of Artemisia princeps pampanini SS-1. Arch Pharm Res; 2006 Sep;29(9):752-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these fermented agents, SS-1 extract fermented with Bifidobacterium infantis K-525 (F-SS-1) most effectively inhibited the release of P-hexosamindase from RBL-2H3 cells induced IgE.
  • In IgE-induced RBL-2H3 cells, F-SS-1 inhibited proinflammatory cytokines IL-6 and TNF-alpha mRNA expression.
  • [MeSH-minor] Animals. Cell Line. Feces / microbiology. Female. Fermentation. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis. Plant Extracts / pharmacology. Pruritus / chemically induced. Pruritus / drug therapy. Reverse Transcriptase Polymerase Chain Reaction. beta-N-Acetylhexosaminidases / metabolism. p-Methoxy-N-methylphenethylamine / adverse effects

  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024848.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Plant Extracts; 33X04XA5AT / Lactic Acid; 4091-50-3 / p-Methoxy-N-methylphenethylamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


34. Knipping K, van Esch EC, Wijering SC, van der Heide S, Dubois AE, Garssen J: In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood); 2008 Nov;233(11):1469-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of drugs that can be used for the treatment of allergic disease is important in human health.
  • AL was selected out of 10,000 herbal extracts in a set-up for high throughput screening in which the degree of degranulation was monitored by the release of beta-hexosaminidase from rat basophil leukemia (RBL-2H3) cells.
  • Although arctiin, the active component of AL that has been described in the literature, was not able to reduce degranulation in RBL-2H3 cells, a single high-performance liquid chromatography (HPLC) fraction from the AL extract inhibited beta-hexosaminidase release (IC(50) = 22.2 microg/ml).
  • In addition, this active component was able to inhibit acute skin response in mice in vivo, indicating that AL is a very promising natural component for use in anti-allergic treatment.
  • [MeSH-minor] Animals. Basophil Degranulation Test. Basophils / drug effects. Basophils / metabolism. Chemical Fractionation. Chromatography, High Pressure Liquid. Ear Diseases / chemically induced. Ear Diseases / drug therapy. Edema / chemically induced. Edema / drug therapy. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Leukotrienes / biosynthesis. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703753.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Anti-Inflammatory Agents; 0 / Leukotrienes; 0 / Plant Extracts
  •  go-up   go-down


35. Bae EA, Min SW, Lee B, Kim NJ, Baek NI, Han EJ, Chung HG, Kim DH: Antiasthmic effect of fermented Artemisia princeps in asthmic mice induced by ovalbumin. J Microbiol Biotechnol; 2007 Sep;17(9):1554-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonetheless, AP and FAP both inhibited the mRNA expression of IL-6 and TNF-alpha in IgE-induced RBL-2H3 cells.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Artemisia / chemistry. Asthma / drug therapy. Bifidobacterium / metabolism. Lung / drug effects
  • [MeSH-minor] Animals. Fermentation. Hypersensitivity / prevention & control. Immunoglobulin E. Interleukin-4. Interleukin-6. Mice. Mice, Inbred BALB C. Models, Animal. Ovalbumin / blood. Ovalbumin / immunology. Plant Extracts / pharmacology. Pruritus / chemically induced. Pruritus / drug therapy. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062237.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Interleukin-6; 0 / Plant Extracts; 0 / RNA, Messenger; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 9006-59-1 / Ovalbumin
  •  go-up   go-down


36. Trinh HT, Bae EA, Lee JJ, Kim DH: Inhibitory effects of curcuminoids on passive cutaneous anaphylaxis reaction and scratching behavior in mice. Arch Pharm Res; 2009 Dec;32(12):1783-7
Hazardous Substances Data Bank. CURCUMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These curcuminoids also inhibited degranulation, protein expression of TNF-alpha and IL-4, and transcription factor NF-kappaB activation in IAC-induced RBL-2H3 cells.
  • [MeSH-major] Anti-Allergic Agents. Curcuma / chemistry. Curcumin / analogs & derivatives. Curcumin / pharmacology. Passive Cutaneous Anaphylaxis / drug effects. Pruritus / drug therapy. Pruritus / psychology
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Enzyme-Linked Immunosorbent Assay. Immunoglobulin E / immunology. Inflammation Mediators / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Plant Roots / chemistry. p-Methoxy-N-methylphenethylamine / pharmacology

  • MedlinePlus Health Information. consumer health - Itching.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162408.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Inflammation Mediators; 37341-29-0 / Immunoglobulin E; 4091-50-3 / p-Methoxy-N-methylphenethylamine; IT942ZTH98 / Curcumin
  •  go-up   go-down


37. McCloud JM, Jameson JS, Scott AN: Life-threatening sepsis following treatment for haemorrhoids: a systematic review. Colorectal Dis; 2006 Nov;8(9):748-55
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-threatening sepsis following treatment for haemorrhoids: a systematic review.
  • Treatments such as rubber band ligation (RBL), sclerotherapy and excisional surgery have been in use for many years, and recently stapled haemorrhoidopexy, or procedure for prolapsing haemorrhoids (PPH) has gained acceptance.
  • The purpose of this review was to assess the scale of the problem, and identify any predisposing factors, common presenting features, and treatment options in those who suffer these complications.
  • Of these, 17 had undergone RBL, three had sclerotherapy, one had cryotherapy, 10 had excisional surgery and seven had PPH.
  • Most were managed by means of surgery, although a minority survived having received conservative therapy.
  • With the exception of two patients (one of whom was human immunodeficiency virus positive and the other had a drug-induced agranulocytosis) all were well prior to surgery.
  • CONCLUSIONS: Although extremely uncommon, severe sepsis does occur post-treatment for haemorrhoids and all surgeons who treat such patients should be aware of the potential complications and alert to their presenting features.
  • Early presentation without evidence of tissue necrosis may be managed conservatively, although most cases are managed by means of surgery.
  • [MeSH-minor] Gangrene / etiology. Gangrene / therapy. Humans

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hemorrhoids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032319.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


38. Perek D, Brozyna A, Dembowska-Baginska B, Stypinska M, Sojka M, Bacewicz L, Polnik D, Kalicinski P: [Tumours in newborns and infants up to three months of life. One institution experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Newborns and infants up to three months of life are a specific group of population in paediatric oncology due to immaturity of tissues and organs and rarity of neoplastic diseases in this group of patients (pts).
  • There are no strict therapeutic procedures established for these children.
  • THE AIM of our study was to examine distribution of tumours in newborns and infants up to 3 months of age treated in our institution and to present our own experience in the treatment of these patients.
  • Distribution of tumour types in newborns and babies from 1 to 3 months of age was analyzed separately.
  • Due to similar growth pattern, response to treatment and it's side effects in newborns and small infants, treatment results were evaluated for the whole group.
  • There were also 3 cases of soft tissue sarcomas (STS), 2 central nervous system tumours (CNS), 2 retinoblastoma (RB), 2 hepatoblastoma (HB).
  • Eleven pts underwent combined treatment of chemotherapy and surgery: 5 with stage III and IV NBL, 6 with other tumours.
  • Chemotherapy alone was administered to 7 pts in whom local advancement of disease enabled surgery and to pts with RBL.
  • Three out of 7 pts are alive all with RBL.
  • One pt, critically ill, died before any treatment.
  • 2. Newborns and small infants with advanced neoplastic disease, similarly to older children can be cured with chemotherapy.
  • 3. Individual approach is warranted in newborns and small infants and treatment should be carried out in specialized centres.
  • 4. All patients who completed treatment of any tumour type should be followed up by a pediatric oncologist.
  • [MeSH-major] Infant Welfare / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317902.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


39. Stavropoulos A, Karring ES, Kostopoulos L, Karring T: Deproteinized bovine bone and gentamicin as an adjunct to GTR in the treatment of intrabony defects: a randomized controlled clinical study. J Clin Periodontol; 2003 Jun;30(6):486-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deproteinized bovine bone and gentamicin as an adjunct to GTR in the treatment of intrabony defects: a randomized controlled clinical study.
  • OBJECTIVES: To evaluate whether Bio-Oss used as an adjunct to guided tissue regeneration (GTR) improves the healing of 1- or 2-wall intrabony defects as compared with GTR alone, and to examine whether impregnation of Bio-Oss with gentamicin may have an added effect.
  • RESULTS: All treatment modalities resulted in statistically significant clinical improvements after 1 year.
  • Defects treated with GTR alone presented a probing attachment level (PAL) gain of 2.9 mm, a residual PPD (PPD12) of 4.9 mm, a radiographic bone level (RBL) gain of 3.1 mm, and a residual IC (IC12) of 2.7 mm.
  • GTR combined with Bio-Oss did not improve the healing outcome (PAL gain: 2.5 mm; PPD12: 4.9 mm; RBL gain: 2.8 mm; IC12: 3.3 mm).
  • Impregnation of the Bio-Oss with gentamicin 2% mg/ml resulted in clinical improvements (PAL gain: 3.8 mm; PPD12: 4.2 mm; RBL gain: 4.7 mm; IC12: 2.1 mm), superior to those of the other treatment modalities, but the difference was not statistically significant.
  • Defects treated with only flap surgery showed the most inferior clinical response (PAL gain: 1.5 mm; PPD12: 5.1 mm; RBL gain: 1.2 mm; IC12: 4.2 mm) of all groups.
  • Local application of gentamicin, on the other hand, improved the treatment outcome but not to an extent that it was statistically significant.
  • [MeSH-major] Alveolar Bone Loss / drug therapy. Alveolar Bone Loss / surgery. Anti-Bacterial Agents / pharmacology. Bone Regeneration / drug effects. Bone Substitutes / pharmacology. Gentamicins / pharmacology. Guided Tissue Regeneration, Periodontal. Minerals / pharmacology
  • [MeSH-minor] Absorbable Implants. Adult. Animals. Bone Matrix / transplantation. Cattle. Drug Combinations. Female. Humans. Male. Membranes, Artificial. Middle Aged. Polyglactin 910. Surgical Flaps. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Minerals.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795786.001).
  • [ISSN] 0303-6979
  • [Journal-full-title] Journal of clinical periodontology
  • [ISO-abbreviation] J. Clin. Periodontol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bio-Oss; 0 / Bone Substitutes; 0 / Drug Combinations; 0 / Gentamicins; 0 / Membranes, Artificial; 0 / Minerals; 0 / Resolut; 34346-01-5 / Polyglactin 910
  •  go-up   go-down


40. Trinh HT, Bae EA, Hyun YJ, Jang YA, Yun HK, Hong SS, Kim DH: Anti-allergic effects of fermented Ixeris sonchifolia and its constituent in mice. J Microbiol Biotechnol; 2010 Jan;20(1):217-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These constituents inhibited the expression of proinflammatory and allergic cytokines, TNF-alpha and IL-4, and transcription factor, NF-kappaB, activation induced by IgE-antigen complex in RBL-2H3 cells, as well as the degranulation of RBL-2H3 cells induced by an IgE-antigen complex.
  • [MeSH-major] Anti-Allergic Agents / immunology. Asteraceae / immunology. Bacteria / metabolism. Fermentation. Inflammation / drug therapy. Plant Extracts / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134255.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Cytokines; 0 / Plant Extracts
  •  go-up   go-down


41. Han SJ, Ryu SN, Trinh HT, Joh EH, Jang SY, Han MJ, Kim DH: Metabolism of cyanidin-3-O-beta-D-glucoside isolated from black colored rice and its antiscratching behavioral effect in mice. J Food Sci; 2009 Oct;74(8):H253-8
MedlinePlus Health Information. consumer health - Itching.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, to understand the relationship between the metabolism of C3G and its pharmacological effect, we isolated C3G from BCR, anaerobically incubated it with fecal microflora, investigated its metabolite(s) by LC-MS/MS, and measured the antiscratching behavioral effects of C3G and its metabolites.
  • These metabolites also inhibited the expression of allergic cytokines, IL-4 and TNF-alpha, and the activation of their transcription factor, NF-kappaB, in RBL-2H3 cells stimulated with IgE-antigen.
  • [MeSH-major] Anthocyanins / metabolism. Anthocyanins / pharmacology. Anti-Allergic Agents / metabolism. Anti-Allergic Agents / pharmacology. Glucosides / metabolism. Glucosides / pharmacology. Oryza / chemistry. Pruritus / drug therapy. Seeds / chemistry
  • [MeSH-minor] Animals. Cell Degranulation / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / metabolism. Hydroxybenzoates / pharmacology. Interleukin-4 / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. NF-kappa B / metabolism. Rats. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799667.001).
  • [ISSN] 1750-3841
  • [Journal-full-title] Journal of food science
  • [ISO-abbreviation] J. Food Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Anti-Allergic Agents; 0 / Glucosides; 0 / Hydroxybenzoates; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 13306-05-3 / cyanidin; 207137-56-2 / Interleukin-4; 36R5QJ8L4B / protocatechuic acid; 7084-24-4 / cyanidin 3-O-glucoside
  •  go-up   go-down


42. Lee B, Trung Trinh H, Bae EA, Jung K, Kim DH: Mangiferin inhibits passive cutaneous anaphylaxis reaction and pruritus in mice. Planta Med; 2009 Oct;75(13):1415-7
MedlinePlus Health Information. consumer health - Itching.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mangiferin also inhibited the expression of the proinflammatory cytokine TNF-alpha and the IgE-switching cytokine IL-4 as well as transcription factor NF-kappaB activation in RBL-2H3 cells stimulated by IgE-antigen complex.
  • [MeSH-major] Anemarrhena / chemistry. Anti-Allergic Agents / therapeutic use. Passive Cutaneous Anaphylaxis / drug effects. Phytotherapy. Plant Extracts / therapeutic use. Pruritus / drug therapy. Xanthones / therapeutic use

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19533581.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Antigens; 0 / NF-kappa B; 0 / Plant Extracts; 0 / Tumor Necrosis Factor-alpha; 0 / Xanthones; 1M84LD0UMD / mangiferin; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 4091-50-3 / p-Methoxy-N-methylphenethylamine
  •  go-up   go-down


43. Lee B, Trinh HT, Jung K, Han SJ, Kim DH: Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritus. Immunopharmacol Immunotoxicol; 2010 Sep;32(3):357-63
MedlinePlus Health Information. consumer health - Itching.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, sarsasapogenin more potently inhibited degranulation and IL-4 protein expression of RBL-2H3 cells induced by IgE-antigen complex than timosaponin AIII.
  • [MeSH-major] Anemarrhena / chemistry. Anti-Allergic Agents / administration & dosage. Passive Cutaneous Anaphylaxis / drug effects. Pruritus / drug therapy. Rhizome / chemistry. Saponins / administration & dosage. Saponins / therapeutic use. Steroids / therapeutic use
  • [MeSH-minor] Animals. Antigen-Antibody Complex / drug effects. Cells, Cultured. Humans. Immunoglobulin E / analysis. Interleukin-4 / analysis. Intestines / microbiology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Rats. Rats, Sprague-Dawley. Spirostans / administration & dosage. Spirostans / analysis. Spirostans / metabolism. Tumor Necrosis Factor-alpha / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095799.001).
  • [ISSN] 1532-2513
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Antigen-Antibody Complex; 0 / Saponins; 0 / Spirostans; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha; 0 / timosaponin AIII; 0 / timosaponin BIII; 0 / timosaponin D; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; CFS802C28F / sarsasapogenin
  •  go-up   go-down


44. Tewtrakul S, Tansakul P, Panichayupakaranant P: Anti-allergic principles of Rhinacanthus nasutus leaves. Phytomedicine; 2009 Oct;16(10):929-34
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The result indicated that all three compounds possessed very potent anti-allergic activity against antigen-induced beta-hexosaminidase release as a marker of degranulation in RBL-2H3 cells with IC(50) values of 6.9, 8.9 and 6.4 microM, respectively.
  • The mechanisms in the late phase reaction of rhinacanthin-C, -D and -N were found to inhibit TNF-alpha and IL-4 gene expression in antigen-induced TNF-alpha and IL-4 releases on from RBL-2H3 cells as dose-dependent manners.
  • The finding may support the traditional use of R. nasutus leaves for treatment of allergy and allergy-related diseases.
  • [MeSH-major] Acanthaceae / chemistry. Anti-Allergic Agents / isolation & purification. Hypersensitivity, Immediate / drug therapy. Naphthoquinones / therapeutic use. Phytotherapy
  • [MeSH-minor] Animals. Cell Line. Drug Evaluation, Preclinical. Molecular Structure. Plant Extracts / therapeutic use. Plant Leaves / chemistry. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403288.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Naphthoquinones; 0 / Plant Extracts; 0 / rhinacanthin-C; 0 / rhinacanthin-D; 0 / rhinacanthin-N
  •  go-up   go-down


45. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V: New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol; 2006 Jan;147(1):83-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (b) assays of transient receptor potential of the vanilloid type-1 (TRPV1) channel functional activity (measurement of [Ca(2+)](i));.
  • (c) [(14)C]AEA cellular uptake and hydrolysis assays in rat basophilic leukaemia (RBL-2H3) cells;.
  • These data confirm the potential utility of selective AEA uptake inhibitors as anti-spasticity drugs in MS and, given the very subtle chemical differences between potent and weak inhibitors of uptake, support further the existence of a specific mechanism for this process.
  • [MeSH-major] Arachidonic Acids / antagonists & inhibitors. Multiple Sclerosis / drug therapy. Muscle Spasticity / drug therapy. Neuromuscular Blocking Agents / pharmacology. Polyunsaturated Alkamides / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 2;404(6773):84-7 [10716447.001]
  • [Cites] Eur J Pharmacol. 2003 Jun 27;471(3):185-93 [12826237.001]
  • [Cites] Pharmacol Ther. 2004 Nov;104(2):117-35 [15518883.001]
  • [Cites] Eur J Pharmacol. 2004 Jan 26;484(2-3):249-57 [14744610.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:619-31 [12432948.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 23;281(2):444-51 [11181068.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1473-81 [12732359.001]
  • [Cites] FEBS Lett. 2000 Oct 13;483(1):52-6 [11033355.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:345-58 [15464149.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5802-7 [10318965.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):275-84 [10448105.001]
  • [Cites] FASEB J. 2001 Feb;15(2):300-2 [11156943.001]
  • [Cites] Eur J Biochem. 2001 Apr;268(7):1982-9 [11277920.001]
  • [Cites] Bioorg Med Chem. 2004 Oct 1;12(19):5161-9 [15351399.001]
  • [Cites] J Neurochem. 2005 Mar;92(6):1327-39 [15748152.001]
  • [Cites] Eur J Pharmacol. 2004 May 10;492(1):1-11 [15145699.001]
  • [Cites] Biochem Pharmacol. 1995 Jun 29;50(1):83-90 [7605349.001]
  • [Cites] Eur J Pharmacol. 2002 Mar 29;439(1-3):83-92 [11937096.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3315-23 [9013571.001]
  • [Cites] Br J Pharmacol. 2000 Jan;129(2):227-30 [10694225.001]
  • [Cites] FASEB J. 2005 Aug;19(10):1338-40 [15941768.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97 [7575630.001]
  • [Cites] Biochemistry. 2004 Jun 29;43(25):8184-90 [15209515.001]
  • [Cites] Nat Rev Drug Discov. 2004 Sep;3(9):771-84 [15340387.001]
  • [Cites] J Org Chem. 1996 May 31;61(11):3849-3862 [11667239.001]
  • [Cites] Nature. 1994 Dec 15;372(6507):686-91 [7990962.001]
  • [Cites] Eur Neuropsychopharmacol. 2006 Jan;16(1):7-18 [16006105.001]
  • [Cites] Biochem J. 2004 May 15;380(Pt 1):265-72 [14969584.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Mar;300(3):984-91 [11861807.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8756-61 [15138300.001]
  • [Cites] Cell Mol Life Sci. 2005 Feb;62(3):386-95 [15723173.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Nov;40(3):471-8 [1666911.001]
  • [Cites] Br J Pharmacol. 2003 Nov;140(5):802-8 [12970089.001]
  • [Cites] Science. 1992 Dec 18;258(5090):1946-9 [1470919.001]
  • [Cites] Nature. 1996 Nov 7;384(6604):83-7 [8900284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4269-74 [12655057.001]
  • [Cites] Pain. 2000 Nov;88(2):205-15 [11050376.001]
  • [Cites] J Med Chem. 2003 Apr 10;46(8):1512-22 [12672252.001]
  • (PMID = 16284631.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA008904; United States / NIDA NIH HHS / DA / DA-09789; United Kingdom / Multiple Sclerosis Society / / 835; United Kingdom / Multiple Sclerosis Society / / 541; United States / NIDA NIH HHS / DA / P01 DA009789; United States / NIDA NIH HHS / DA / DA-08904
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Endocannabinoids; 0 / Neuromuscular Blocking Agents; 0 / Polyunsaturated Alkamides; UR5G69TJKH / anandamide
  • [Other-IDs] NLM/ PMC1615845
  •  go-up   go-down


46. Joo SS, Won TJ, Nam SY, Kim YB, Lee YC, Park SY, Park HY, Hwang KW, Lee DI: Therapeutic advantages of medicinal herbs fermented with Lactobacillus plantarum, in topical application and its activities on atopic dermatitis. Phytother Res; 2009 Jul;23(7):913-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic advantages of medicinal herbs fermented with Lactobacillus plantarum, in topical application and its activities on atopic dermatitis.
  • The use of herbal medicines in the therapeutic treatment of atopic dermatitis (AD) has been suggested recently.
  • Furthermore, the release of beta-hexosaminidase in RBL-2H3 mast cells was suppressed significantly.
  • In conclusion, the results presented in this study suggest that FHE may have therapeutic advantages for the treatment of AD due to its increased immune-suppressive and increased absorptive effects, which were fortified by L. plantarum fermentation.
  • [MeSH-major] Dermatitis, Atopic / drug therapy. Immunosuppressive Agents / pharmacology. Lactobacillus plantarum / metabolism. Plant Extracts / pharmacology
  • [MeSH-minor] Administration, Topical. Animals. Cell Line. Cell Proliferation / drug effects. Chromatography, High Pressure Liquid. Cytokines / metabolism. Disease Models, Animal. Fermentation. Herbal Medicine. Immunoglobulin E / blood. Male. Mice. Plants, Medicinal. Skin / pathology. Spleen / cytology. Spleen / metabolism. Th1 Cells / drug effects. Th1 Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • (PMID = 19145636.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunosuppressive Agents; 0 / Plant Extracts; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


47. Choi YH, Lim H, Heo MY, Kwon DY, Kim HP: Anti-inflammatory activity of the ethanol extract of Chungkukjang, Korean fermented bean: 5-lipoxygenase inhibition. J Med Food; 2008 Sep;11(3):539-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-inflammatory activity of Chungkukjang, a Korean traditional fermented soybean food (Korean-style Natto), was examined for the first time.
  • From the results, it was found that the ethanol extract of Chungkukjang inhibited 5-lipoxygenase from A23187-treated RBL-1 cells, reducing leukoriene production (50% inhibitory concentration = 54.1 microg/mL).
  • Since leukotrienes are intimately involved in some allergic disorders, the anti-allergic activity of Chungkukjang was further examined in animal models of passive cutaneous anaphylaxis (type I hypersensitivity) and arachidonic acid-induced ear edema, two well-known in vivo models sensitive to 5-lipoxygenase inhibitors.
  • [MeSH-major] Inflammation / drug therapy. Inflammation Mediators / metabolism. Isoflavones / therapeutic use. Lipoxygenase Inhibitors / therapeutic use. Plant Extracts / therapeutic use. Soybean Proteins / therapeutic use. Soybeans
  • [MeSH-minor] Animals. Arachidonate 5-Lipoxygenase / metabolism. Arachidonic Acid / metabolism. Ear. Edema / drug therapy. Fermentation. Hypersensitivity / drug therapy. Lipopolysaccharides / pharmacology. Male. Mice. Mice, Inbred ICR. Nitric Oxide / biosynthesis. Phytotherapy. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800904.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Isoflavones; 0 / Lipopolysaccharides; 0 / Lipoxygenase Inhibitors; 0 / Plant Extracts; 0 / Soybean Proteins; 0 / chungkookjang; 27YG812J1I / Arachidonic Acid; 31C4KY9ESH / Nitric Oxide; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


48. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, Kim SD, Jo EJ, Lee YN, Lee C, Baek SH, Bae YS: Serum amyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Mol Pharmacol; 2006 Jul;70(1):241-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stimulation of formyl peptide receptor-like-1-expressing RBL-2H3 cells, but not of vector-expressing RBL-2H3 cells with serum amyloid A, induced mitogen-activated protein kinases activation and the accumulation of the RNAs of these two cytokines.
  • [MeSH-major] Monocytes / drug effects. Receptors, Formyl Peptide / metabolism. Serum Amyloid A Protein / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Chromones / pharmacology. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Flavonoids / pharmacology. Humans. Imidazoles / pharmacology. Interleukin-10 / biosynthesis. Interleukin-10 / genetics. Morpholines / pharmacology. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Nitriles / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Pyridines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sulfones / pharmacology. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors. p38 Mitogen-Activated Protein Kinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569709.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / 3-(4-methylphenylsulfonyl)-2-propenenitrile; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Morpholines; 0 / NF-kappa B; 0 / Nitriles; 0 / Pyridines; 0 / RNA, Messenger; 0 / Receptors, Formyl Peptide; 0 / SB 203580; 0 / Serum Amyloid A Protein; 0 / Sulfones; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


49. Otsu K, Sato K, Ikeda Y, Imai H, Nakagawa Y, Ohba Y, Fujii J: An abortive apoptotic pathway induced by singlet oxygen is due to the suppression of caspase activation. Biochem J; 2005 Jul 1;389(Pt 1):197-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Singlet oxygen causes the cytotoxic process of tumour cells in photodynamic therapy.
  • To address this issue, we synthesized and used two types of endoperoxides, MNPE (1-methylnaphthalene-4-propionate endoperoxide) and NDPE (naphthalene-1,4-dipropionate endoperoxide), that generate defined amounts of singlet oxygen at 37 degrees C with similar half lives.
  • RBL cells, a rat basophil leukaemia-derived line, that overexpress phospholipid hydroperoxide glutathione peroxidase in mitochondria were found to be highly resistant to the cytotoxic effect of MNPE.
  • MNPE treatment induced much less DNA ladder formation and nuclear fragmentation in cells than etoposide treatment, even though these treatments induced a similar extent of cellular damage.
  • [MeSH-minor] Caspases / metabolism. Cell Line, Tumor. Cell-Free System. Cytochromes c / metabolism. Cytochromes c / secretion. Enzyme Activation / drug effects. Glutathione / metabolism. Humans. Hydrophobic and Hydrophilic Interactions. Lipid Peroxides / pharmacology. Mitochondria / enzymology. Mitochondria / secretion. Molecular Structure. Naphthols / pharmacology. Propionates / pharmacology. Selenium / metabolism. Tocopherols. Vitamin E / analogs & derivatives. Vitamin E / metabolism. beta Carotene / metabolism

  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 2001 Apr 15;30(8):825-35 [11295525.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29294-302 [10506188.001]
  • [Cites] FEBS Lett. 2001 Jul 6;500(3):114-8 [11445067.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Biol Chem. 2002 Mar-Apr;383(3-4):443-56 [12033434.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 15;32(12):1293-303 [12057767.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):289-92 [12220676.001]
  • [Cites] Free Radic Biol Med. 2003 Jan 15;34(2):145-69 [12521597.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3298-307 [12433931.001]
  • [Cites] Biochem J. 2003 May 1;371(Pt 3):1055-64 [12605597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 6;305(3):761-70 [12763058.001]
  • [Cites] Anal Bioanal Chem. 2003 Jun;376(4):444-7 [12719955.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2202-8 [14656982.001]
  • [Cites] Biochem J. 2004 Jan 1;377(Pt 1):241-8 [14531733.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9 [14680842.001]
  • [Cites] Photochem Photobiol Sci. 2004 Jan;3(1):17-25 [14743273.001]
  • [Cites] Methods Enzymol. 1985;113:548-55 [4088074.001]
  • [Cites] Nucleic Acids Res. 1991 Oct 25;19(20):5792 [1945860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12365-7 [7809042.001]
  • [Cites] J Biochem. 1996 Apr;119(4):817-22 [8743587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14586-91 [8962096.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):215-27 [9008715.001]
  • [Cites] FEBS Lett. 1997 May 26;408(3):289-91 [9188778.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25719-23 [9325297.001]
  • [Cites] J Biol Chem. 2000 Mar 3;275(9):6067-70 [10692394.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):2984-9 [10716721.001]
  • [Cites] Methods Enzymol. 2000;319:197-207 [10907511.001]
  • [Cites] Methods Enzymol. 2000;319:342-58 [10907525.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):25939-48 [10837470.001]
  • [Cites] Photochem Photobiol. 2000 Oct;72(4):548-53 [11045728.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] FEBS Lett. 2000 Nov 10;484(3):280-4 [11078893.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):221-32 [10998365.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):183-93 [10998361.001]
  • [Cites] J Exp Med. 1997 Nov 17;186(10):1763-8 [9362536.001]
  • [Cites] FEBS Lett. 1998 Jul 31;432(1-2):9-12 [9710240.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] FEBS Lett. 1998 Nov 20;439(3):329-33 [9845348.001]
  • [Cites] J Invest Dermatol. 1999 Jan;112(1):3-12 [9886256.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4924-33 [9988735.001]
  • [Cites] Eur J Biochem. 1999 Mar;260(3):917-22 [10103024.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11549-56 [10206961.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15345-9 [10336420.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17325-33 [10358093.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):203-12 [10388534.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22686-92 [10428850.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):647-50 [10471379.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):999-1010 [11381085.001]
  • (PMID = 15796713.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-(4'-methyl-1'-naphthyl)propionic acid 1',4'-endoperoxide; 0 / Caspase Inhibitors; 0 / Lipid Peroxides; 0 / Naphthols; 0 / Propionates; 01YAE03M7J / beta Carotene; 1406-18-4 / Vitamin E; 1406-66-2 / Tocopherols; 17778-80-2 / Singlet Oxygen; 9007-43-6 / Cytochromes c; 97860-59-8 / 3,3'-(1,4-naphthylidene)diproprionate; EC 3.4.22.- / Caspases; GAN16C9B8O / Glutathione; H6241UJ22B / Selenium
  • [Other-IDs] NLM/ PMC1184552
  •  go-up   go-down


50. Ramires R, Caiaffa MF, Tursi A, Haeggström JZ, Macchia L: Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun; 2004 Nov 12;324(2):815-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast.
  • Particularly, cysteinyl-leukotrienes have been recognized as playing a significant role in the pathophysiology of asthma and potent and effective Cys-LT1 receptor antagonists have been developed for the treatment of this illness.
  • Here we report that montelukast, a structural Cys-LT1 receptor antagonist, also exerts a substantial and apparently direct inhibitory effect on 5-lipoxygenase activity in vitro, at concentrations in the lower micromolar range, which are of potential therapeutic relevance.
  • Similar results were obtained in the rat mast cell-like RBL-1 cell model (IC50 congruent with 2.5 microM) and in human polymorphonuclear leukocytes.
  • Kinetic experiments revealed that the inhibition was of the non-competitive type, suggesting that montelukast binds a yet undefined allosteric site on 5-lipoxygenase.
  • 5-Lipoxygenase inhibition by montelukast appears to be highly selective since the drug had no effects on other enzymes of the leukotriene cascade, viz.
  • [MeSH-major] Acetates / pharmacology. Anti-Asthmatic Agents / pharmacology. Asthma / drug therapy. Lipoxygenase Inhibitors. Quinolines / pharmacology
  • [MeSH-minor] Allosteric Site. Animals. Calcimycin / pharmacology. Calcium / metabolism. Catalysis. Cell Line. Cell Line, Tumor. Cell Survival. Cells, Cultured. Chromatography, High Pressure Liquid. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. HL-60 Cells. Humans. Inhibitory Concentration 50. Kinetics. Leukotriene B4 / metabolism. Leukotriene C4 / metabolism. Mast Cells / drug effects. Neutrophils / metabolism. Protein Binding. Rats. Recombinant Proteins / chemistry

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • Hazardous Substances Data Bank. MONTELUKAST .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15474500.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Anti-Asthmatic Agents; 0 / Lipoxygenase Inhibitors; 0 / Quinolines; 0 / Recombinant Proteins; 1HGW4DR56D / Leukotriene B4; 2CU6TT9V48 / Leukotriene C4; 37H9VM9WZL / Calcimycin; 7S5I7G3JQL / Dexamethasone; MHM278SD3E / montelukast; SY7Q814VUP / Calcium
  •  go-up   go-down


51. Malaviya R, Uckun FM: Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)phenyl]propenamide inhibits IgE/FcepsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice. Am J Ther; 2001 Sep-Oct;8(5):309-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed that the novel LFM analogue, alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl) phenyl]propenamide (LFM-A8), is a more potent inhibitor than LFM of IgE/FcepsilonRI receptor-mediated LTC4 release from RBL-2H3 rat mast cells.
  • Treatment of ovalbumin (OVA)-sensitized mice with LFM-A8 prevented the development of airway hyperresponsiveness to methacholine in a dose-dependent fashion.
  • Therefore further development of compound LFM-A8 may provide the basis for new and effective treatment programs for severe allergic disorders, including allergic asthma.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Isoxazoles / pharmacology. Mast Cells / drug effects
  • [MeSH-minor] Animals. Asthma / drug therapy. Asthma / physiopathology. Leukotriene C4 / metabolism. Mice. Mice, Inbred BALB C. Receptors, IgE / drug effects. Structure-Activity Relationship

  • Hazardous Substances Data Bank. LEFLUNOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11550070.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Isoxazoles; 0 / Receptors, IgE; 2CU6TT9V48 / Leukotriene C4; G162GK9U4W / leflunomide
  •  go-up   go-down


52. Oka T, Fujimoto M, Nagasaka R, Ushio H, Hori M, Ozaki H: Cycloartenyl ferulate, a component of rice bran oil-derived gamma-oryzanol, attenuates mast cell degranulation. Phytomedicine; 2010 Feb;17(2):152-6
MedlinePlus Health Information. consumer health - Allergy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IgE-targeting therapy could provide significant progress in the treatment of allergic inflammation.
  • CAF and gamma-oryzanol also inhibited the degranulation of DNP-IgE sensitized RBL-2H3 mast cells stimulated with anti-DNP-HSA.
  • [MeSH-major] Cell Degranulation / drug effects. Coumaric Acids / pharmacology. Hypersensitivity / drug therapy. Mast Cells / drug effects. Phenylpropionates / pharmacology. Plant Extracts / pharmacology. Plant Oils / chemistry
  • [MeSH-minor] Animals. Antibodies, Anti-Idiotypic / blood. Dinitrophenols. Enzyme-Linked Immunosorbent Assay. Immunoglobulin E / blood. Inflammation / blood. Inflammation / drug therapy. Male. Oryza / chemistry. Passive Cutaneous Anaphylaxis / drug effects. Phytotherapy. Rats. Rats, Sprague-Dawley. Receptors, IgE / metabolism. Serum Albumin. Skin / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19577449.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Coumaric Acids; 0 / Dinitrophenols; 0 / Phenylpropionates; 0 / Plant Extracts; 0 / Plant Oils; 0 / Receptors, IgE; 0 / Serum Albumin; 0 / anti-IgE antibodies; 0 / cycloartenyl ferulate; 0 / dinitrophenyl-human serum albumin conjugate; 37341-29-0 / Immunoglobulin E; 68553-81-1 / rice bran oil; SST9XCL51M / gamma-oryzanol
  •  go-up   go-down


53. Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T: Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Curr Drug Discov Technol; 2004 Jan;1(1):1-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile.
  • Function oriented synthesis provides a means to address this supply problem through the design of synthetically more accessible simplified structures that at the same time incorporate improved functional activity.
  • More significantly, the described molecule retains the functional ability to translocate a PKCdelta-GFP fusion protein in RBL cells.
  • [MeSH-major] Drug Design. Macrolides / chemical synthesis. Macrolides / pharmacology. Protein Kinase C / metabolism
  • [MeSH-minor] Animals. Bryostatins. Cell Line, Tumor. Image Processing, Computer-Assisted. Indicators and Reagents. Isoenzymes / chemistry. Isoenzymes / metabolism. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / metabolism. Microscopy, Fluorescence. Models, Molecular. Protein Binding. Rats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472215.001).
  • [ISSN] 1570-1638
  • [Journal-full-title] Current drug discovery technologies
  • [ISO-abbreviation] Curr Drug Discov Technol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31845; United States / NIMH NIH HHS / MH / MH064801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Bryostatins; 0 / Indicators and Reagents; 0 / Isoenzymes; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


54. Joo SS, Kim SG, Choi SE, Kim YB, Park HY, Seo SJ, Choi YW, Lee MW, Lee DI: Suppression of T cell activation by hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis. Eur J Pharmacol; 2009 Jul 1;614(1-3):98-105
Genetic Alliance. consumer health - Eczema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of T cell activation by hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis.
  • The increasing prevalence and severity of atopic dermatitis during recent decades has prompted the development of safe and more highly effective drugs.
  • Although topical corticosteroids have been used for more than 50 years as first line therapy for atopic dermatitis, their potential side effects limits their clinical uses.
  • In light of this, steroid-free topical calcineurin inhibitors were developed and have been used in patients with moderate to severe atopic dermatitis.
  • In the present study, we examined if hirsutenone suppressed the profiles of atopic dermatitis development in vitro via mimicry of calcineurin inhibitor actions in mouse splenocytes and RBL-2H3 mast cells.
  • Therefore, our results suggest that hirsutenone may be a new topical drug candidate, which probably acts by mimicking calcineurin inhibitor mechanisms.
  • [MeSH-major] Alnus / chemistry. Catechols / isolation & purification. Catechols / pharmacology. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / immunology. Diarylheptanoids / isolation & purification. Diarylheptanoids / pharmacology. Plant Bark / chemistry. T-Lymphocytes / drug effects
  • [MeSH-minor] Animals. Antibodies / immunology. Antigens, CD3 / immunology. Biomarkers / metabolism. Biomimetics. Calcineurin Inhibitors. Cell Proliferation / drug effects. Cytokines / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Immunosuppressive Agents / isolation & purification. Immunosuppressive Agents / pharmacology. Immunosuppressive Agents / therapeutic use. Interleukin-2 Receptor alpha Subunit / antagonists & inhibitors. Lymphocyte Activation / drug effects. Mast Cells / drug effects. Mast Cells / secretion. Mice. NFATC Transcription Factors / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Signal Transduction / drug effects. Th1 Cells / drug effects. Th2 Cells / drug effects. beta-N-Acetylhexosaminidases / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409888.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Biomarkers; 0 / Calcineurin Inhibitors; 0 / Catechols; 0 / Cytokines; 0 / Diarylheptanoids; 0 / Immunosuppressive Agents; 0 / Interleukin-2 Receptor alpha Subunit; 0 / NFATC Transcription Factors; 0 / RNA, Messenger; 0 / hirsutenone; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


55. Bae YS, Lee HY, Jo EJ, Kim JI, Kang HK, Ye RD, Kwak JY, Ryu SH: Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol; 2004 Jul 1;173(1):607-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study we identified several novel peptides by screening hexapeptide libraries that inhibit the binding of one of FPRL1's agonists (Trp-Lys-Tyr-Met-Val-D-Met-CONH(2) (WKYMVm)) to its specific receptor, FPRL1, in RBL-2H3 cells.
  • WRW(4) is the first specific FPRL1 antagonist and is expected to be useful in the study of FPRL1 signaling and in the development of drugs against FPRL1-related diseases.
  • [MeSH-major] Oligopeptides / pharmacology. Receptors, Formyl Peptide / antagonists & inhibitors. Receptors, Lipoxin / antagonists & inhibitors. Signal Transduction / drug effects


56. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D, Newman RA: Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate; 2003 Jun 1;55(4):281-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 12-MTA was evaluated by MTT assay for its ability to inhibit cell proliferation in various cancer types.
  • Furthermore, alteration of eicosanoid metabolism by 12-MTA was examined in PC3 and RBL-1 cells and in purified lipoxygenase (LOX) and cyclooxygenase (COX) enzymes.
  • This agent may be a novel adjunctive therapy for selected malignancies including prostate cancer.
  • [MeSH-major] Fatty Acids / pharmacology. Lipoxygenase Inhibitors. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / enzymology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Arachidonate 5-Lipoxygenase / metabolism. Caspase 3. Caspases / metabolism. Cell Division / drug effects. Cyclooxygenase Inhibitors / pharmacology. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Female. Flow Cytometry. Growth Inhibitors / pharmacology. Humans. Hydroxyeicosatetraenoic Acids / metabolism. Male. Microscopy, Electron, Scanning. Prostaglandin-Endoperoxide Synthases / metabolism. Rats. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12712407.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Fatty Acids; 0 / Growth Inhibitors; 0 / Hydroxyeicosatetraenoic Acids; 0 / Lipoxygenase Inhibitors; 467RNW8T91 / 5-hydroxy-6,8,11,14-eicosatetraenoic acid; 5502-94-3 / aseanostatin P5; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


57. Jeon JH, Kwon SC, Park D, Shin S, Jeong JH, Park SY, Hwang SY, Kim YB, Joo SS: Anti-allergic effects of white rose petal extract and anti-atopic properties of its hexane fraction. Arch Pharm Res; 2009 Jun;32(6):823-30
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the cell level, the hexane fraction markedly inhibited beta-hexosaminidase release from RBL-2H3 mast cells and suppressed the expressions of mRNA interferon-gamma and interleukin-4 cytokines produced by T helper cells (type 1 and 2).
  • These results strongly support that the hexane fraction may have an effect on atopic dermatitis, as these 2 cell types play central roles in the pathogenesis of atopic dermatitis.
  • In conclusion, these results suggest that either the hexane fraction or one of its components may be beneficial for the treatment of allergic diseases, including atopic dermatitis.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Hexanes / pharmacology. Hypersensitivity, Immediate / drug therapy. Phytotherapy. Plant Extracts / pharmacology. Rosa
  • [MeSH-minor] Anaphylaxis / chemically induced. Anaphylaxis / drug therapy. Animals. Cells, Cultured. Cytokines / metabolism. Drug Evaluation, Preclinical. Flowers / chemistry. Histamine / pharmacology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis / drug effects. Spleen / drug effects. Spleen / metabolism. beta-N-Acetylhexosaminidases / secretion. p-Methoxy-N-methylphenethylamine / pharmacology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557358.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Cytokines; 0 / Hexanes; 0 / Plant Extracts; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 820484N8I3 / Histamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


58. Lee JH, Kim JW, Ko NY, Mun SH, Kim DK, Kim JD, Won HS, Shin HS, Kim HS, Her E, Kim YM, Choi WS: Mast cell-mediated allergic response is suppressed by Sophorae flos: inhibition of SRC-family kinase. Exp Biol Med (Maywood); 2008 Oct;233(10):1271-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complementary and alternative medicines are considered as a promising direction for the development of anti-allergic therapies in oriental countries.
  • Sophorae flos exhibited a significant inhibitory effect on degranulation in antigen-stimulated mast cells with IC(50) values of approximately 31.6 microg/mL (RBL-2H3 mast cells) and approximately 47.8 microg/mL (bone marrow-derived mast cells).
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Hypersensitivity / drug therapy. Mast Cells / metabolism. Sophora. src-Family Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Antigens / pharmacology. Cells, Cultured. Disease Models, Animal. Immunoglobulin E / metabolism. Interleukin-4 / metabolism. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis / drug effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Allergy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641055.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Drugs, Chinese Herbal; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


59. Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG: Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res; 2001 Sep;44(3):213-20
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LDP-392 is 17.9-fold more potent than zileuton (5-LO inhibitor) in the RBL cytosolic 5-LO assay, and equally potent as MK 287 (PAF receptor antagonist) in the human platelet PAF receptor binding assay.
  • [MeSH-minor] Animals. Arachidonate 5-Lipoxygenase / metabolism. Dose-Response Relationship, Drug. Edema / drug therapy. Erythema / drug therapy. Female. Guinea Pigs. Humans. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11529688.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / CMI 392; 0 / Furans; 0 / Lipoxygenase Inhibitors; 0 / Platelet Activating Factor; 0 / Platelet Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / platelet activating factor receptor; 8W8T17847W / Urea; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


60. Wallmann J, Proell M, Stepanoska T, Hantusch B, Pali-Schöll I, Thalhamer T, Thalhamer J, Jensen-Jarolim E, Hartl A: A mimotope gene encoding the major IgE epitope of allergen Phl p 5 for epitope-specific immunization. Immunol Lett; 2009 Jan 29;122(1):68-75
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an RBL assay, mimotope-specific IgG antibodies were able to prevent cross-linking of allergen-specific IgE by Phl p 5.
  • We therefore suggest that mimotope gene vaccines are potential candidates for epitope-specific immunotherapy of type I allergy.
  • [MeSH-minor] Animals. Biomimetic Materials. Cell Degranulation / genetics. Cell Degranulation / immunology. Cell Line, Tumor. Desensitization, Immunologic. Female. Genetic Engineering. Genetic Therapy. Immunoglobulin G / blood. Interferon-gamma / secretion. Lymphocyte Activation / genetics. Lymphocyte Activation / immunology. Mice. Mice, Inbred BALB C. Pollen. Rats

  • MedlinePlus Health Information. consumer health - Hay Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2001 Jul 27;502(1-2):46-52 [11478946.001]
  • [Cites] FASEB J. 2001 Nov;15(13):2524-6 [11641259.001]
  • [Cites] Vaccine. 2002 Aug 19;20(25-26):3148-54 [12163266.001]
  • [Cites] Clin Exp Allergy. 2002 Nov;32(11):1583-8 [12569978.001]
  • [Cites] Mol Immunol. 2003 May;39(14):847-54 [12686500.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1999-2005 [12902504.001]
  • [Cites] Microbes Infect. 2003 Sep;5(11):939-46 [12941385.001]
  • [Cites] Clin Exp Allergy. 2003 Sep;33(9):1171-4 [12956735.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):915-22 [14610480.001]
  • [Cites] Methods. 2004 Mar;32(3):321-7 [14962767.001]
  • [Cites] Methods. 2004 Mar;32(3):328-39 [14962768.001]
  • [Cites] Adv Exp Med Biol. 1989;251:215-8 [2481962.001]
  • [Cites] Gene. 1995 Mar 21;155(1):61-5 [7698668.001]
  • [Cites] J Virol. 1996 Sep;70(9):6119-25 [8709236.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2278-84 [9036975.001]
  • [Cites] J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):107-13 [9893193.001]
  • [Cites] Allergy. 1999 Jun;54(6):552-61 [10435468.001]
  • [Cites] FASEB J. 1999 Sep;13(12):1586-92 [10463950.001]
  • [Cites] J Allergy Clin Immunol. 2004 Dec;114(6):1294-300 [15577826.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):585-97 [16248827.001]
  • [Cites] Mol Immunol. 2006 Mar;43(9):1454-61 [16150491.001]
  • [Cites] Allergy. 2006 Jul;61(7):828-35 [16792580.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):269-76 [16815165.001]
  • [Cites] J Allergy Clin Immunol. 2006 Sep;118(3):734-41 [16950295.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10567-75 [17079481.001]
  • [Cites] Mol Immunol. 2007 Mar;44(8):1879-87 [17070909.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3406-11 [17409451.001]
  • [Cites] Vaccine. 2000 Mar 6;18(17):1725-9 [10699319.001]
  • [Cites] Infect Immun. 2000 Oct;68(10):5914-9 [10992502.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2177-84 [11053238.001]
  • [Cites] Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):395-7 [11307026.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1558-65 [11466377.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6501-8 [17975163.001]
  • [Cites] Mol Immunol. 2008 Mar;45(5):1308-17 [17964653.001]
  • [Cites] Methods Mol Med. 2008;138:271-83 [18612616.001]
  • (PMID = 19111573.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / F 1808
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunodominant Epitopes; 0 / Immunoglobulin G; 0 / Phl p V protein, Phleum pratense; 0 / Plant Proteins; 37341-29-0 / Immunoglobulin E; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2999763; NLM/ UKMS32994
  •  go-up   go-down


61. Lim BO, Lee JH, Ko NY, Mun SH, Kim JW, Kim DK, Kim JD, Kim BK, Kim HS, Her E, Lee HY, Choi WS: Polygoni cuspidati radix inhibits the activation of Syk kinase in mast cells for antiallergic activity. Exp Biol Med (Maywood); 2007 Dec;232(11):1425-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extract of PR exhibited potent inhibitory activity in mast cells; its IC50 values were 62 +/- 2.1 microg/ml for RBL-2H3 mast cells and 46 +/- 3.2 microg/m for bone marrow-derived mast cells by antigen stimulation, and it also suppressed the expression of tumor necrosis factor-alpha and interleukin-4 in RBL-2H3 cells.
  • [MeSH-major] Anaphylaxis / drug therapy. Anti-Allergic Agents / pharmacology. Fallopia japonica. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Mast Cells / enzymology. Plant Extracts / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Antigens / pharmacology. Bone Marrow Cells / enzymology. Bone Marrow Cells / pathology. Cell Line. Disease Models, Animal. Enzyme Activation / drug effects. Histamine / metabolism. Inflammation / drug therapy. Inflammation / enzymology. Interleukin-4 / biosynthesis. MAP Kinase Kinase 4 / metabolism. Male. Mice. Mice, Inbred ICR. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / drug effects. Tumor Necrosis Factor-alpha / biosynthesis

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040066.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Antigens; 0 / Intracellular Signaling Peptides and Proteins; 0 / Plant Extracts; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 820484N8I3 / Histamine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


62. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy; 2000;55 Suppl 64:17-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells.
  • This notion is supported by the fact that structurally unrelated drugs antagonize the H1-receptor and provide clinical benefit.
  • On the basis of in vitro and animal experiments, drugs classified as H1-receptor antagonists have long been recognized to have additional pharmacological properties.
  • These additional properties are not uniformly distributed among drugs classified as H1-receptor antagonists.
  • In addition, it inhibits arachidonic acid-induced paw oedema in rats without affecting carrageenin-induced rat paw oedema, suggesting an effect on LT generation.
  • It also inhibits anaphylactic release of histamine from rodent mast cells, LTC4 and LTB4 release from mouse bone-marrow-derived mast cells, LTC4 release from rat intestinal mast cells, and 5-lipoxygenase activity of polymorphonuclear neutrophils of guinea-pig intestines and rat basophilic leukaemia cells.
  • It is equally clear that these antiallergic effects are not uniformly shared among all drugs of this class.
  • [MeSH-major] Anti-Allergic Agents / immunology. Histamine H1 Antagonists / immunology. Histamine H1 Antagonists / therapeutic use. Hypersensitivity / drug therapy. Hypersensitivity / immunology
  • [MeSH-minor] Animals. Benzimidazoles / immunology. Benzimidazoles / therapeutic use. Disease Models, Animal. Humans. Receptors, Histamine H1 / immunology. Rhinitis / drug therapy. Rhinitis / immunology

  • MedlinePlus Health Information. consumer health - Allergy.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291777.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI45583; United States / NIDCD NIH HHS / DC / DC 02714
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Benzimidazoles; 0 / Histamine H1 Antagonists; 0 / Receptors, Histamine H1; 244O1F90NA / mizolastine
  • [Number-of-references] 34
  •  go-up   go-down






Advertisement